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Abstract 
Treatment of bacterial illnesses has become increasingly difficult as the 
development of new antibiotics is being outpaced by the increasing number of antibiotic-
resistant organisms.  This has led us to search for alternative therapeutic approaches to help 
combat these illnesses.  A viable approach in treating these illnesses is to focus on 
inhibiting protein toxins, which are one of the many virulence factors that bacteria secrete.  
Many toxins recognize and bind to cholesterol (Chol) on the host cell membrane as an 
initial step in their mechanism; however, a viable method of inhibiting this interaction has 
yet to be uncovered. 
For our model toxin, which recognizes and binds to Chol, we have chosen the 
repeats-in-toxin (RTX) toxin leukotoxin A (LtxA) secreted by the Gram-negative 
bacterium Aggregatibacter actinomycetemcomitans.  LtxA functions by resisting the host’s 
immune response by binding to and killing white blood cells via Chol within their 
membrane.  This association with Chol is regulated by a Chol recognition amino acid 
consensus (CRAC) motif, with a sequence of 334LEEYSKR340, in the N-terminal 
(hydrophobic) region of the toxin. 
Here, we have demonstrated LtxA’s requirement for Chol; removal of Chol from 
the plasma membrane of leukocytes inhibits the activity of the toxin.  We have shown that 
a peptide designed from LtxA’s CRAC motif (CRACWT) has a similar affinity for Chol and 
can inhibit LtxA cytotoxicity by binding to Chol and preventing subsequent LtxA binding 
and internalization.  Utilizing biophysical techniques, we characterized the interaction 
between CRACWT and Chol and found that the hydroxyl group within Chol is key to this 
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interaction and that CRACWT does not disrupt membrane packing, suggesting that 
CRACWT primarily sits near the water-membrane interface. 
To further improve upon the interaction between CRACWT and Chol-containing 
membranes, we investigated the effect of altering the net charge of CRACWT to create a 
peptide that binds to Chol with a stronger affinity.  We synthesized four CRACWT mutants 
that corresponded to an increase or decrease in the overall net charge of CRACWT.  To 
measure the affinities of these mutants for Chol-containing membranes, as well as their 
ability to inhibit LtxA cytotoxicity, we employed localized surface plasmon resonance 
(LSPR) measurements and cell-based assays respectively.  We found that neither 
decreasing nor increasing the net charge of CRACWT led to an increase in the peptide’s 
affinity for Chol-containing membranes, but mutants with high net charges were incapable 
of inhibiting LtxA cytotoxicity. 
Next, to determine the significance that each residue within the CRAC motif has 
on the peptide’s ability to bind to membrane Chol, we synthesized 10 CRAC peptide 
mutants.  Each peptide mutant had one residue within the CRAC domain substituted with 
an alanine residue.  We found that seven of the ten residues within the CRAC motif have 
a significant effect on the peptide’s affinity for Chol-containing membranes, with the most 
prominent residues being the three highlighted in the CRAC domain definition, leucine 
(Leu), tyrosine (Tyr), and arginine (Arg). 
Finally, to test the efficacy of CRACWT in vitro against other Chol-binding 
pathogens we utilized two Streptococcal toxins, streptolysin O (SLO) and pneumolysin O 
(PLO), which are considered important virulence factors for this genus.  We investigated 
the inhibitory effect of CRACWT on the cytotoxic and hemolytic activity of SLO and PLO 
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and found that CRACWT inhibited the cytotoxicity of SLO and PLO, as well as the 
hemolytic activity of PLO in a concentration-dependent fashion. 
These results suggest that CRACWT holds potential clinical applicability to treat not 
just bacterial illnesses but potentially other viruses that utilize Chol during pathogenesis 
since features of the CRAC motif have been implicated in the function of proteins relevant 
to the human immunodeficiency virus (HIV), the influenza virus (flu), and the herpes 
simplex virus. 
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Chapter 1  
Introduction and Background 
1.1 Introduction 
Every year bacterial infections are becoming increasingly challenging to treat as 
bacteria quickly develop resistance due to the increased exposure they receive from the 
overuse and misuse of antibiotics, which results in more antibiotic-resistant organisms [1, 
2].  Currently, out of the 18 drug-resistant threats that the United States Centers for Disease 
Control and Prevention (CDC) is monitoring, bacteria are responsible for 17 of them [3].  
Furthermore, antibiotics that were once successful in treating such organisms are now 
rendered obsolete, and the rate of development for new antibiotics to treat these emerging 
pathogens has been declining since the 1980’s [3, 4].  This has led to an estimated two 
million people developing antibiotic-resistant infections annually in the United States, with 
more than 23,000 of those infections resulting in fatalities, thus leading to costs estimated 
to be US$21-34 billion a year for the U.S. health care system [3, 5].  Furthermore, many 
large pharmaceutical companies have cut funding into the research and development of 
antibiotics due to the increased difficulty of discovering new antibiotics and the increased 
costs of clinical trials [5-7]. 
1.2 Antibiotic Alternatives 
The decrease in effectiveness of antibiotics has led us and many others to search 
for alternative options that could be utilized in their place, or in combination [3, 8, 9].  
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Some of the current alternative treatments strategies which are highlighted below include 
antimicrobial peptides, antibacterial monoclonal antibodies, and vaccines [10-13]. 
1.2.1 Antimicrobial Peptides 
The increasing rise of bacterial resistance to conventional antibiotics has led to 
many studies focusing on the use of antimicrobial peptides (AMPs) as an alternative 
treatment option for antibiotic-resistant bacteria due to their effectiveness against these 
organisms [14-19].  This is leading the global peptide drug market to experience a rapid 
growth that is projected to increase to US$25.4 billion in 2018, up from US$14.1 billion in 
2011, thus making the exploration of peptide therapeutics worthwhile [20].  Furthermore, 
AMPs have many advantages over traditional therapeutics.  They have a rapid onset of 
activity, low levels of induced resistance, and broad-spectrum capabilities allowing them 
to target and inhibit numerous infectious Gram-positive and Gram-negative bacteria and 
their virulence factors [21-25]. 
Although AMPs can offer various advantages over traditional treatments they come 
with numerous disadvantages as well  .They are sensitive to environmental conditions 
making them vulnerable to hydrolysis, oxidation, and aggregation, which decreases the 
success of transferring an AMP effective treatment from in vitro to in vivo [10, 12, 25-29].  
While their sensitivity to the environment can lead to limitations, several groups are 
focusing on improving their stability in these conditions with the use of D amino acids and 
structural modifications [30-32]. 
Currently there are several AMPs in development that show promise against a 
variety of microbial infections.  These include PAC-113 that targets infections in HIV 
patients, LTX-109 that treats methicillin-resistant and vancomycin resistant 
6 
 
Staphylococcus aureus skin infections, and hLF1-11 that targets fatal bacterial and fungal 
infections for immunocompromised stem cell transplant patients [33-36]. 
1.2.2 Monoclonal Antibodies 
Antibacterial monoclonal antibodies (AMAs) offer another potential avenue of 
treatment as they have demonstrated success against bacterial infections and cancer in vitro 
in vivo [37-39].  Due to their effectiveness against certain cancers their popularity has risen 
and paved the way for significant improvements in the manufacturing and production of 
AMAs thus driving down their cost and making them a cost-effective alternative 
therapeutic in the treatment of bacterial infections [37, 40]. 
AMAs provide numerous advantages over current antibiotics.  They tend to have a 
lower risk of side effects, they can be synthesized into bispecific antibodies for increased 
potency and targetability, they do not harm the host’s microbiome, they can be designed to 
incorporate multiple inhibitory mechanisms, and most importantly they induce less 
selective pressure for cross-resistance [41-45].  Even with advances to their production and 
manufacturing they are still very expensive to produce versus small-molecule therapeutics 
and only a very limited number of clinical studies have been performed supporting AMA 
treatments [40, 46].  Furthermore, their ability to target outer membrane proteins as 
potential epitopes in bacterial infections is reduced by the exopolysaccharides masking of 
those targets thus making them less effective in these situations [47-49]. 
Even with these limitations several AMAs have found success against bacteria.  
BiS4αPa is utilized against Pseudomonas aeruginosa, a multidrug resistant bacterium that 
is the leading cause of lung infections in patients suffering from cystic fibrosis and hospital-
acquired pneumonia [50, 51].  BiS4αPa inhibits P. aeruginosa from successfully attaching 
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to epithelial cells and it increases the host’s ability to clear the pathogen through 
phagocytosis [51, 52].  The AMA bezlotoxumab has also been utilized against the 
Clostridium difficile cytotoxin, Toxin B, which acts by binding to the toxin and inhibiting 
it from binding to the cell lining of the gut [53-55]. 
1.2.3 Vaccines 
Vaccines have also been studied for their potential antibacterial effects [56].  Two 
major benefits of their applicability toward bacterial infections is the potential reduction of 
antibiotics use they will provide if rendered effective, which will result in decreased 
antibiotic-resistant bacteria and provide herd protection against their target bacterial 
disease [57].  While many of the most effective vaccines are live attenuated mutant 
vaccines, they are also the most harmful because they are unsafe for immunocompromised 
individuals [58, 59].  Other limitations also exist for combination vaccines such as DTaP 
which protect against diphtheria, tetanus, and acellular pertussis [60].  Furthermore, if there 
is an adverse reaction from a combination vaccine, it would lead to an uncertainty in the 
cause of the reaction and additionally these treatments are costly with a complex 
administration process [61].  Lastly, another vaccine limitation arises from the 
development of single antigen targeting vaccines since they tend to be less effective than 
the vaccines mentioned previously due to differences in the target’s antigenic expression 
[57]. 
Currently, there are numerous vaccines in development or that have been developed 
against pathogenic bacteria.  A live attenuated strain vaccine (ΔtrxA) for multi-drug 
resistant Acinetobacter baumannii, which causes nosocomial and combat related 
infections, has been has shown to be effective in treating this infection in murine models 
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[62].  MeNZB, an outer membrane vesicle meningococcal vaccine, has been developed to 
target Neisseria gonorrhoeae, the bacterium responsible for gonorrhea and potential 
infertility in females [63, 64].  Lastly, VLA84, a vaccine against the diarrhea causing C. 
difficile and SA4Ag, a vaccine against vancomycin resistant S. aureus, have also shown 
promise in the inhibition of their respective targets [55, 65-68]. 
1.2.4 Antivirulence Strategies 
One potential pathway for treatments involves focusing on bacterial virulence 
factors instead of directly killing the bacterium [69, 70].  Virulence factors are molecules 
produced by bacteria that allow them to defend themselves and infect their host.  These 
include effector molecules, enzymes, adhesins, and toxins [71]. 
A majority of antivirulence studies focus on targeting secreted protein toxins 
utilizing a variety of mechanisms.  For example, the blocking of membrane pores formed 
by pore-forming toxins has found success as an alternative antivirulence strategy.  Utilizing 
cyclodextrin derivatives, these molecules are able to bind to and block transmembrane 
pores formed by the lethal pore-forming bacterial toxins secreted by Bacillus anthracis and 
several Staphylococcal toxins, which include α-hemolysin and γ-hemolysin [72, 73]. 
Another potential avenue of inhibition is targeting the membrane environment of 
the target cell.  In a separate study, we found that we could alter the properties of the cell 
membrane to inhibit toxin activity.  Using the nuclear stain DRAQ5™, we demonstrated 
that the stain reduced the fluidity of the membrane which prevented leukotoxin A (LtxA) 
of Aggregatibacter actinomycetemcomitans from binding to the membrane, thus inhibiting 
the cytotoxicity of this toxin [74]. 
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Antivirulence strategies that target the toxins directly after secretion from the cell 
have also been developed.  Protein toxins released by the bacterial genera Escherichia, 
Campylobacter, Salmonella, Shigella, and Vibrio bind to intestinal cells and lead to diseases 
including cholera and travellers' diarrhea [75-77].  To inhibit toxin-cell interactions, 
carbohydrate-based scaffolds have been engineered to mimic the membrane glycolipid 
environment that the toxins utilize in their pathogenic mechanism.  The scaffolds intercept the 
toxin before it reaches the cell, allowing the toxin to bind to the scaffold instead of the 
targeted cellular membrane leading to an inhibition of cytotoxicity.  
In addition, several inhibitors have been found for the cholera toxin.  These 
inhibitors, Geldanamycin, sodium 4-phenylbutyrate, and a group of polyphenolic 
compounds, act in targeting molecular chaperones, subunits of the cholera toxin, or the 
entire toxin respectively [78-80].  Geldanamycin, which is an anti-cancer agent, inhibits 
cholera toxin cytotoxicity by blocking the cytosolic chaperone Hsp90, thus preventing the 
A1 subunit of cholera toxin from passing into the cytosol [79].  Sodium 4-phenylbutyrate, 
a drug used to treat urea cycle deficiencies, has been found to prevent thermal unfolding of 
the A1 subunit of cholera toxin which inhibits cholera toxin cytotoxicity as well [78].  
Lastly, a group of polyphenolic compounds (polyphenols) have been found to inhibit 
cholera toxin and other structurally similar toxins including a diphtheria toxin, and ricin in 
numerous ways [80].  Polyphenols can inhibit cholera toxin by preventing the toxin from 
binding to the cell membrane, stripping the toxin from the cell membrane, inhibiting the 
activity of the toxin’s A1 subunit, or by blocking its cytosolic activity [80]. 
In this study we present a novel antivirulence strategy against a bacterial exotoxin.  
Utilizing a peptide derived from the protein LtxA in the repeats-in-toxin (RTX) toxin 
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family, we demonstrate that we can use this peptide to inhibit LtxA from binding to the 
membrane, thus preventing cytotoxicity. 
1.3 RTX Toxins and LtxA 
One class of toxins that are secreted by bacteria and used in pathogenesis are protein 
exotoxins.  A specific class of protein exotoxins is the RTX family of toxins.  RTX toxins 
are characterized by nonapeptide aspartate-rich and glycine-rich repeats, along with a 
common method of secretion across the bacterial membrane through the type 1 secretion 
system [81].  The family includes toxins secreted by Escherichia coli, Bordetella pertussis, 
and Vibrio cholerae, as well as three genera listed on the CDC’s report of the biggest 
antimicrobial threats, Streptococcus, Enterobacteriaceae, and Campylobacter [3, 81]. 
To investigate a potential peptide therapeutic to treat these emerging threats, we 
use LtxA (sequence shown in Figure 1.3) as a model RTX toxin, which is secreted by the 
bacterium A. actinomycetemcomitans.  A. actinomycetemcomitans is a Gram-negative 
pathogenic bacterium that has a significant role in localized juvenile periodontitis, as well 
as nonoral infections including endocarditis and pneumonia [82, 83]. 
A. actinomycetemcomitans expresses and secretes two protein toxins that allow it 
to avoid the host’s immune system, cytolethal distending toxin (CDT) which kills host cells 
by blocking their proliferation and LtxA which kills host cells by disrupting their 
membrane environment [84-89].  Furthermore, it has been shown that the virulence of A. 
actinomycetemcomitans is correlated with the amount of LtxA secreted; strains with most 
LtxA secretion (JP2 strains) are correlated to the most severe cases of illness versus strains 
that produce the least amount of LtxA (652 strains) [90-96]. 
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1.3.1 Mechanism and Structure of LtxA 
Once LtxA is secreted it acts by specifically attacking the host’s immune response, 
killing off any defending leukocytes of humans and Old-World primates [97-101].  This 
binding of LtxA to leukocytes is facilitated by its interaction with membrane Chol and it 
has been shown that removal of Chol or blocking of Chol inhibits the toxin’s activity [17, 
19, 102, 103].  Once bound to the cell, it has been suggested that LtxA utilizes the 
lymphocyte function-associated receptor 1 (LFA-1) of the cell membrane to orient itself 
into a conformation state that allows it to begin its cytotoxic mechanism as shown in Figure 
1.1 [87, 104]. 
LtxA contains four unique regions.  The N-terminal region (hydrophobic domain), 
consisting of residues 1–408 (green highlighted region in Figure 1.3), contains multiple 
hydrophobic and hydrophilic domains, as shown by the positive and negative peaks 
respectively in Figure 1.2 between the 0 to 408 position.  Furthermore, it has been 
suggested that the hydrophobic region between residues 175-400 penetrate the membrane 
(Figure 1.1) and facilitate LtxA’s cytotoxicity [87, 105, 106].  The central domain of LtxA 
(residues 409–729), as shown by the gray highlighted region in Figure 1.3, contains the 
fatty acid chains that are believed to be critical in the initial binding stages of LtxA to the 
cell membrane [107].  Located between residues 730-900 is the repeat domain (turquoise 
highlighted region in Figure 1.3) associated with all RTX toxins.  This region contains 
multiple nonapeptide aspartate-rich and glycine-rich repeats and has been linked to the 
protein’s interaction with LFA-1, as shown in Figure 1.1 [98, 101, 103, 105, 108].  Finally, 
the C-terminal domain (teal highlighted region in Figure 1.3) contains residues 730-900 
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and is only believed to play a role in the toxin’s secretion from A. actinomycetemcomitans 
and not in the toxin’s interaction with the cellular membrane [109]. 
A. actinomycetemcomitans, which secretes LtxA, is resistant to multiple antibiotics 
(amoxicillin, clindamycin, and doxycycline) which are commonly used to initially treat 
this infection; if such antibiotics fail the next course of treatment is usually surgery [110-
114].  Since LtxA attacks hematopoietic cells from humans and Old-World primates and 
is associated with the severe illnesses caused by A. actinomycetemcomitans, LtxA make an 
excellent virulence factor to target therapeutically. 
 
 
 
Figure 1.1 Interaction of LtxA with target cell membrane 
The N-terminal region and the fatty acids in the central domain interact with the membrane 
to facilitate LtxA to the membrane and the repeat region interacts with LFA-1 [87, 115]. 
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Figure 1.2 Hydrophobicity scale of LtxA 
Positive values represent hydrophobic domains and negative values represent hydrophilic 
domains. 
 
 
LtxA     1 MATTTLPNTKQQAAQFANSVADRAKENIDAAKEQLQKALDKLGKTGKKLTLYIPKNYKKG 
LtxA    61 NGLTALIKAAQKLGIEVYHEGKDGPALTNGILNTGKKLLGLTERGLTLFAPELDKWIQGN 
LtxA   121 KHLSNSVGSTGNLTKAIDKVQSVLGTLQAFLNTAFSGMDLDALIKARQNGKNVTDVQLAK 
LtxA   181 ASLNLINELIGTISSITNNVDTFSKQLNKLGEALGQVKHFGSFGDKLKNLPKLGNLGKGL 
LtxA   241 GALSGVLSAISAALLLANKDADTATKAAAAAELTNKVLGNIGKAITQYLIAQRAAAGLST 
LtxA   301 TGPVAGLIASVVSLAISPLSFLGIAKQFDRARMLEEYSKRFKKFGYNGDSLLGQFYKNTG 
LtxA   361 IADAAITTINTVLSAIAAGVGAASAGSLVGAPIGLLVSAITSLISGILDASKQAVFEHIA 
LtxA   421 NQLADKIKAWENKYGKNYFENGYDARHSAFLEDSLKLFNELREKYKTENILSITQQGWDQ 
LtxA   481 RIGELAGITRNGDRIQSGKAYVDYLKKGEELAKHSDKFTKQILDPIKGNIDLSGIKGSTT 
LtxA   541 LTFLNPLLTAGKEERKTRQSGKYEFITELKVKGRTDWKVKGVPNSNGVYDFSNLIQHAVT 
LtxA   601 RDNKVLEARLIANLGAKDDYVFVGSGSTIVNAGDGYDVVDYSKGRTGALTIDGRNATKAG 
LtxA   661 QYKVERDLSGTQVLQETVSKQETKRGKVTDLLEYRNYKLDYYYTNKGFKAHDELNSVEEI 
LtxA   721 IGSTLRDKFYGSKFNDVFHGHDGDDLIYGYDGDDRLYGDNGNDEIHGGQGNDKLYGGAGN 
LtxA   781 DRLFGEYGNNYLDGGEGDDHLEGGNGSDILRGGSGNDKLFGNQGDDLLDGGEGDDQLAGG 
LtxA   841 EGNDIYVYRKEYGHHTITEHSGDKDKLSLANINLKDVSFERNGNDLLLKTNNRTAVTFKG 
LtxA   901 WFSKPNSSAGLDEYQRKLLEYAPEKDRARLKRQFELQRGKVDKSLNNKVEEIIGKDGERI 
LtxA   961 TSQDIDNLFDKSGNKKTISPQELAGLIKNKGKSSSLMSSSRSSSMLTQKSGLSNDISRII 
LtxA   1021 SATSGFGSSGKALSASPLQTNNNFNSYANSLATTA 
 
Figure 1.3 Sequence of LtxA 
The putative CRAC motif within LtxA is highlighted in yellow. The N-terminal region 
(residues 1-408) is highlighted in green, the central domain (residues 409–729) is 
highlighted in gray, the repeat region (residues 730-900) is highlighted in turquoise, and 
the C-terminal region (residues 901-1055) is highlighted in teal. 
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1.3.2 Interaction of LtxA and Chol 
The toxicity of LtxA against host cells is critical on its ability to bind to Chol within 
the plasma membrane of the cell.  The affinity of LtxA for Chol is regulated in part by a 
putative Chol recognition amino acid consensus (CRAC) motif within the protein’s 
primary structure as shown by the yellow highlighted region in Figure 1.3 [102].  This work 
focuses on the interaction of this CRAC domain with Chol and its potential as an alternative 
therapeutic against Chol-dependent bacterial toxins. 
 
 
Figure 1.4 CRACWT blocks the recognition of Chol by the toxin. 
 
1.4 Background of the CRAC Motif 
1.4.1 Membrane Chol 
A cell membrane’s main function is to protect the interior of the cell from its 
surroundings with Chol being one of the membrane’s primary components [116, 117].  
Chol functions by maintaining membrane structure and dynamics, while also facilitating 
membrane protein function [116-120].  In the case of the membrane proteins known as G 
protein coupled receptors (GPCRs), which include the cannabinoid receptor, the opioid 
receptor, rhodopsin, and the β2-adrenergic receptor, Chol regulates their functions, 
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dynamics, and oligomerization [121-123].  Many extracellular pathogenic proteins also 
utilize Chol as one of their key binding sites in the cell membrane or in Chol-rich domains 
known as lipid rafts [117-119, 124-129].  Many of these pathogenic proteins that bind to 
Chol include the gp41 protein of HIV-1, the influenza virus M2 protein, intermedilysin 
(ILY) of Streptococcus intermedius, and LtxA of A. actinomycetemcomitans [130-133]. 
A number of pathogens, such as the ones mentioned above, recognize Chol through 
a variety of different Chol-binding domains which include the sterol-sensing domain 
(SSD), the Chol recognition motif (CRM) of Chol-dependent cytolysins, and the CRAC 
motif [131, 134, 135].  The SSD is a domain with a unique interaction and affinity for Chol 
[134].  It is composed of approximately 180 amino acids which form five adjacent 
membrane spanning domains [134].  SSDs are implicated in the NPC1 protein which 
mediates Chol trafficking and is required in the production of HIV-1 and the cell entry of 
the Ebola virus [136, 137].  The CRM of Chol-dependent cytolysins is composed of a 
threonine and Leu pair which facilitates the binding of pathogens, such as ILY, 
perfringolysin O (PFO), pneumolysin O (PLO), and streptolysin O (SLO) to Chol [133, 
135].  Lastly, the CRAC motif, which has been mentioned previously, is also a domain 
with an affinity for Chol [131].  Pathogenic proteins that contain an active CRAC motif 
include LtxA and CDT, as well as the viral protein gp41, which is critical in the 
pathogenesis of HIV-1 [102, 130, 138]. 
1.4.2 Discovery and History of the CRAC Motif 
Utilizing computational methods to investigate protein-membrane interactions 
involving Chol led to the discovery of several potential Chol-binding domains within 
proteins, with one of these domains being the CRAC motif [131, 139-143].  An important 
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feature of this motif is the presence of three key amino acids, which are a central aromatic 
residue, a positively charged basic residue, and a hydrophobic residue [140]. 
The CRAC motif was first proposed in 1998 and was based on the active Chol 
binding site of 20 proteins, with a majority of those proteins being the translocator protein 
(formally known as the peripheral-type benzodiazepine receptor) and the Chol side-chain 
cleavage cytochrome P450scc of numerous species [131, 144].  It is defined as follows, the 
first residue needs to be a Leu or a Val, the next residue(s) (up to five residues) can be any 
amino acid, this is then followed by a key central Tyr residue that is required, then the next 
residue(s) (up to five residues) can be any amino acid, and finally the sequence is concluded 
with a Lys or an Arg [140, 142, 143, 145].  This CRAC definition is stylized as (L/V)-(X1-
5)-Y-(X1-5)-(K/R). 
Location of the CRAC motif varies between proteins but it is essential that the 
CRAC motif of any protein be found at the protein’s membrane-interacting region.  For 
this reason CRAC sequences are usually found adjacent to transmembrane helices as in the 
case of the HIV-1 fusion protein gp41, but have also been found to coexist between the 
transmembrane domain and the extracellular regions of the protein as in the nicotinic 
acetylcholine receptor protein [139, 145-147].  Furthermore, CRAC motifs are also found 
in non-transmembrane proteins.  These amphipathic proteins contain CRAC regions that 
are exposed on the surface of the protein where they bind to Chol within the membrane; 
examples include the cytolethal distending toxin C (CdtC) and LtxA, both of A. 
actinomycetemcomitans [102, 138].  For example, when LtxA is interacting with a cell 
membrane, its CRAC domain (Figure 1.3) is believed to reside in the protein’s extracellular 
and transmembrane regions as shown in Figure 1.1. 
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Based on the CRAC algorithm definition, a CRAC domain can range from five to 
13 residues in length which leads to a possible 1.02 x 1013 CRAC sequences [143].  This 
leaves the biggest issue with this domain unaddressed; the algorithm is not well defined 
and is very inaccurate.  It overpredicts Chol-binding domains to the point where many of 
these domains do not have an affinity for Chol, thus making these domains a difficult topic 
to study [102, 148-151].  For example, our model bacterial protein toxin, LtxA of A. 
actinomycetemcomitans, contains 12 putative CRAC motifs within its primary structure, 
but only one has demonstrated an affinity for Chol, while the neurotensin receptor 1, a 
transmembrane protein, contains two putative CRAC motifs with neither having an affinity 
for Chol [102, 152].   
1.4.3 Prevalence of the CRAC Motif in Medically Relevant Pathogens 
The CRAC motif has been identified and implicated in Chol binding of numerous 
medically relevant proteins, including gp41 protein of HIV-1, the influenza virus M2 
protein, and the Herpes virus [130-132].   
The CRAC motif of gp41 is found adjacent to its transmembrane domain [130].  
Although the exact mechanism of the CRAC domain in gp41 is not known, it is believed 
that this CRAC domain plays a role in the fusogenic ability of the virus [153, 154]. 
Mutations to the CRAC domain of gp41 resulted in a decrease of fusogenic ability and 
studies performed with a peptide derivative of gp41’s CRAC domain further supported 
these findings [153, 155]. 
The M2 protein of the influenza virus was also found to contain a putative CRAC 
motif.  This motif is located immediately downstream of the transmembrane domain of M2 
[156].  The CRAC domain of M2 is suggested to facilitate membrane targeting of the 
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protein; subsequent mutations to the central Tyr of the CRAC domain reduced the ability 
of the M2 protein mutant to bind to Chol-containing liposomes [132]. 
Through an in silico analysis another putative viral CRAC motif was discovered 
within the Herpes virus [157].  This CRAC domain is situated in the domain responsible 
for the refolding of critical viral proteins during the fusion step of virus internalization 
[157, 158]. 
CRAC motifs are also present in an important class of transmembrane proteins that 
has been shown to bind Chol, GPCRs.  GPCRs that contain CRAC motifs include 
rhodopsin, the β2-adrenergic receptor, and the serotonin1A receptor [159].  These proteins 
participate in critical bodily functions including visual transduction and serving as 
receptors for neurotransmitters and hormones [160-162].  Two proposed functions of 
CRAC motifs in GPCRs include inducing conformational changes that facilitate binding 
between a GPCR and Chol, or indirectly changing membrane properties of the surrounding 
GPCR environment to facilitate a more favorable conformational state for the protein [163-
168].  Furthermore, the mechanism of how the CRAC motifs, of the mentioned GPCRs, 
interact with Chol is still undetermined [123, 169-171].   
1.4.4 CRAC Domain’s Interaction with Chol 
Previously, other groups have tried to investigate certain characteristics that 
regulate the CRAC domain’s affinity for Chol.  One group performed several studies to 
investigate the significance that the primary structure of a CRAC peptide, derived from the 
gp41 protein of HIV-1, had on its ability to sequester Chol [143, 172, 173].  In this study, 
the initial, final, and central residues of the CRAC domain were determined to be critical 
to the peptide’s ability to sequester Chol [143].  It was also found that their CRAC peptide 
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favors Lys over Arg due to the increased structural flexibility that it provides and the ability 
of Arg to bring the peptide closer to the membrane-water interface due to its more polar 
side chain [143].  Furthermore, the peptide’s conformation was found to affect the peptide’s 
ability to bind to Chol when it interacts with the membrane, additionally this study also 
found that the peptide’s effectiveness is also dependent on small changes to the amino acid 
composition.  A follow up study demonstrated an increase in their peptide’s ability to 
sequester Chol when they substituted out X residues for glycine, which provides the 
greatest rotational freedom of any amino acid [173].  Lastly, they found that substituting 
the critical initial residue with an alanine decreased the peptide’s ability to sequester Chol 
[172]. 
Studies performed on CRAC domain’s in viruses that investigate mutations to 
the central Tyr residue or to the initial and final residue of the CRAC motif have found 
these changes to negatively affect virion structure organisation with the Chol-containing 
membranes [131, 157, 174-176].  In addition, studies involving full length proteins have 
found that the Tyr residue within the protein’s CRAC motifs is critical in its ability to bind 
to Chol [17, 138, 177, 178].  Any changes to the CRAC domain’s central Tyr was found to 
result in a decreased sensitivity for membrane Chol [173, 174, 177-179]. 
The importance of these residues for binding to Chol cannot be understated because 
they each play a unique role in driving a CRAC motif’s interaction with Chol.  For example, 
it is believed that the Leu or Val uses its branched side chains to associate with the β face 
of Chol (Figure 1.5) through van der Waals interactions and to accommodate the 
molecule’s unique structure [140, 180, 181].  The central Tyr, the most essential residue in 
the recognition of Chol, has been found to bind to Chol by means of a CH-π stacking 
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interaction with the B ring of Chol (Figure 1.5), while the hydroxyl group of Tyr allows 
for electrostatic interactions with the sterol’s hydroxyl group as well [140, 142, 181, 182].  
Finally, Lys or Arg, with its lengthy apolar side chains, buries itself into the membrane 
bilayer with the charged group sitting at the membrane surface [140, 183, 184].  This 
distinctive trait allows Arg and Lys to attract water molecules and/or lipid headgroups to 
hydrogen bond with [184-186]. 
 
 
Figure 1.5 Structure of Chol 
 
1.4.5 Structure of the CRAC Motif 
A downside to the analysis of CRAC motifs is that there is a lack of high resolution 
structural information available for this Chol-binding motif.  Furthermore, there is also a 
lack of structural information on proteins which contain CRAC domains that interact with 
Chol in lipid membranes [149].  This deficiency in structural information has been 
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suggested to reduce the chance to predict a successful binding CRAC motif [140].  The 
limited amount of structural data that is available comes from computational simulations 
and an experimental data set.  For the case of the CRAC peptide from the protein LtxA of 
A. actinomycetemcomitans, its structure in solution is composed of β-sheets, α-helices, and 
random coils.  Once the peptide interacts with Chol-containing membranes significant 
changes to its secondary structure occur.  This results in a decreased α-helical structure and 
β-sheet propensity and leads to an increased coil conformation as it interacts with Chol in 
the membrane [182].  In addition, one circular dichroism (CD) study performed on a CRAC 
peptide derived from the gp41 protein of HIV-1 has found that as the CRAC peptide 
transitions from a solution environment to an environment composed of lipid and Chol the 
peptide’s helical structure increased [187]. 
1.5 Use of the CRAC Motif as an Antivirulence Strategy 
Many bacterial and viral pathogens recognize Chol as an initial step in their activity 
against host cells [17, 188, 189].  Demonstrating the effectiveness of this Chol-binding 
peptide to inhibit the interaction between a virulence factor and Chol introduces a novel 
strategy that has enormous potential for the treatment of not just illnesses caused by 
bacteria, but also those caused by viruses that utilize Chol, including HIV and the influenza 
virus [17, 188, 189].   
With a Chol-binding peptide, we gain the ability to attack any Chol-dependent 
illnesses, as there are currently no viable approaches to inhibit this interaction.  More 
importantly, CRACWT exhibits no long-term toxicity to white blood cells or short-term 
toxicity to red blood cells, further bolstering its potential as an alternative therapeutic [19].  
Furthermore, the use of these types of peptides has the potential to replace or supplement 
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the use of antibiotics, leading to a decrease in the increasingly rising number of antibiotic 
resistant bacteria. 
Using this CRAC motif within LtxA as a model, we engineered a peptide 
(CRACWT) and demonstrated its inherently strong affinity for Chol-containing membranes 
[19].  CRACWT functions by binding to Chol near the surface of the immune cell’s 
membrane where it blocks the recognition of Chol by the toxin, thus inhibiting membrane 
binding and subsequent toxin internalization, as depicted in Figure 1.4 [19].  This renders 
the bacterial toxin ineffective and allows the immune cells to clear the infection. 
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Chapter 2  
Materials & Methods 
2.1 Chemicals  
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-ditetradecanoyl-sn-
glycero-3-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 
and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) were purchased from 
Avanti Polar Lipids (Alabaster, AL).  Cholesterol (Chol), desmosterol (Desmo), 
dihydrocholesterol (DHC), cholesteryl chloride (CC), 1-Octanol, poly-L-lysine, phorbol 
12-myristate 13-acetate (PMA), methyl-β-cyclodextrin (MβCD), and methyl-β-
cyclodextrin-cholesterol (MβCD-Chol) were purchased from Sigma-Aldrich (St. Louis, 
MO).  Ergosterol (Ergo) was purchased from MP Biomedicals (Solon, OH).  N-(7-
Nitrobenz-2-Oxa-1,3-Diazol-4-yl)-1,2-Dihexadecanoyl-sn-Glycero-3-
Phosphoethanolamine (NBD-PE) and 6-Dodecanoyl-2-Dimethylaminonaphthalene 
(Laurdan) were manufactured by Molecular Probes (Eugene, OR).   
2.2 LtxA purification 
A. actinomycetemcomitans strain JP2 was grown overnight in AAGM broth 
supplemented with 12.5 µg/ml vancomycin and 75 µg/ml bacitracin [190].  LtxA was 
purified as described previously [191].  The toxin was confirmed to be free of any 
impurities by SDS-PAGE, Coomassie staining, and western blot, as shown in Figure 2.1, 
and activity was confirmed using a cytotoxicity assay (data not shown). 
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Figure 2.1 Coomassie stain and immunoblot (western blot) of purified LtxA. 
 
2.3 Liposome Preparation 
2.3.1 Large Unilamellar Vesicles 
Liposomes were prepared using the lipid film technique.  Stock solutions of lipids 
at 25 mg/mL were prepared in chloroform and then added to a glass vial in the required 
amounts [192].  The chloroform was evaporated under a stream of nitrogen, and the 
residual chloroform was removed under vacuum to create a thin lipid film on the glass 
surface.  Multilamellar liposomes (MLVs) were created by hydrating the lipid film with 
buffer.  The MLVs were then extruded through a 100-nm polycarbonate Whatman 
membrane (GE Healthcare Bio-Sciences, Pittsburgh, PA) with a LiposoFast® extruder 
(AVESTIN Inc., Ottawa, ON) to create large unilamellar vesicles (LUVs) [193].   
2.3.1.1 Cell Cytotoxicity Experiments 
Lipids used to create films for this experiment were POPC, Chol, and Ergo.  Lipid 
films were hydrated with PBS (137 mM NaCl, 2.7 mM KCl, Na2PO4, KH2PO4, pH 7.4).  
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Liposomes composed of POPC and Ergo were formed using the rapid solvent exchange 
(RSE) technique [194].  Stock solutions of POPC and Ergo were added to a glass vial, PBS 
was added directly, and the chloroform was evaporated while the solution was vortexed. 
2.3.1.2 ITC and CD Experiments 
Lipids used to create films for this experiment were POPC and Chol.  The lipid 
films were hydrated with a phosphate buffer (10 mM NaH2PO4, pH 6.5). 
2.3.1.3 Laurdan experiments 
Lipids used to create films for this experiment were POPC, DMPC, Chol, DHC, 
Desmo, and CC.  The lipid films were hydrated with a liposome buffer (150 mM NaCl, 5 
mM CaCl2, 5 mM HEPES, and 3 mM NaN3, pH 7.4). 
2.3.2 Giant Unilamellar Vesicles 
Giant unilamellar vesicles (GUVs), were formed from a mixture of 
DOPC/DPPC/Chol/NBD-PE (33/33/33/1 mol%) or POPC/Chol/NBD-PE (66/33/1 mole 
ratio) lipids dissolved in chloroform/acetonitrile (90/10 vol%) for a final lipid 
concentration of 4 mg/mL.  The mixture was spin-coated onto indium tin oxide (ITO) 
coated glass slides (SPI, West Chester, PA) using a Laurell WS-650-23 spin coater [195].  
To remove any remaining solvent, the lipid-coated slides were placed under vacuum for 30 
min.  A polydimethylsiloxane (PDMS) spacer was used to separate two slides and create a 
compartment that was filled with 18.2 MΩ/cm ultrapure water from a Milli-Q® Advantage 
A10 system (EMD Millipore, Billerica, MA), and sealed using binder clips.  For 3 hr at 23 
°C, an electric field was applied to form GUVs [196].  The GUVs were used within the 
same day. 
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2.4 Cell Culture 
THP-1 cells obtained from ATCC were maintained in RPMI 1640 medium 
containing 10% FBS and 0.05 mM 2-mercaptoethanol at 37 °C under 5% CO2.  
2.5 Depletion and Replenishment of Plasma Membrane Chol 
THP-1 cells, maintained in cell culture media, were depleted of Chol through 
incubation with 10 mM MβCD for 15 min at 37 °C and 5% CO2.  After the incubation, the 
cells were washed with cell culture media to remove any excess MβCD and were used in 
the cytotoxicity assay immediately.  To replenish Chol, some of the MβCD-treated cells 
were subjected to an additional incubation with 1 mM MβCD-Chol for 1 hr at 37 °C and 
5% CO2.  These Chol-replenished cells were then washed and used immediately.  The 
concentration of Chol in the THP-1 cell membranes before depletion, after depletion, and 
after replenishment was measured with an Amplex® Red Cholesterol Assay Kit (Life 
TechnologiesTM).  Intensity measurements were performed with an Infinite 200 Pro plate 
reader (Tecan Group Ltd., Männedorf, Switzerland) with an excitation wavelength of 555 
nm and an emission wavelength of 580 nm. 
2.6 Cytotoxicity Assays 
For the cytotoxicity tests, the cell membrane permeability was determined with a 
trypan blue assay using a Countess II automated cell counter (Thermo Fisher Scientific, 
Waltham, MA).  Each experiment was performed three independent times.  Untreated cells 
were used as a control.  Cells were incubated at 37 °C under 5% CO2.  The percentage of 
cells alive after each treatment was calculated using the following equation: 
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𝐶𝑒𝑙𝑙 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 % =  
𝑁ℎ
𝑁0
 
where N0 is the number of cells before treatment, and Nh is the number of cells after h hrs 
of treatment. 
2.6.1 LtxA Cell Cytotoxicity with Chol-Depleted Cells and Chol-Replenished Cells 
using MβCD 
To determine the role of Chol in toxicity of LtxA, Chol-depleted and –replenished 
cells were incubated with 2 µg of LtxA for 3 hr.  Untreated cells, as well as Chol-depleted 
and Chol-replenished cells that had not been treated with LtxA, were used as controls.  
2.6.2 LtxA Cell Cytotoxicity with Chol-Containing Liposomes 
To measure the protective effect of Chol-containing liposomes against LtxA, THP-
1 cells were incubated with (i) LtxA, (ii) LtxA + 100% POPC liposomes, (iii) LtxA + 60% 
POPC/40% Chol liposomes, or (iv) LtxA + 60% POPC/40% Ergo liposomes.  The mass 
of LtxA in each sample was 2 µg, and all liposome concentrations were 9.0 x 10-7 M.  
Controls included PBS, 100% POPC liposomes alone, 60%POPC/40%Chol liposomes 
alone, and 60%POPC/40%Ergo liposomes alone. 
2.6.3 LtxA Cell Cytotoxicity with CRACWT 
To measure the protective effect of the CRACWT peptide against LtxA, THP-1 cells 
were incubated with protein samples containing (i) LtxA, (ii) LtxA + CRACWT, or (iii) 
LtxA + CRACSCR.  The mass of LtxA in each sample was 2 µg, and the molar LtxA:peptide 
ratio was 1:100.  Controls included PBS, CRACWT alone, and CRACSCR alone. 
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2.6.4 SLO Cell Cytotoxicity with CRACWT 
To measure the protective effect of the CRACWT peptide against SLO, THP-1 cells 
were incubated with protein samples containing (i) SLO, (ii) SLO + CRACWT, or (iii) SLO 
+ CRACSCR.  SLO-containing samples were incubated with cells for 24 hr.  The mass of 
SLO in each sample was 40.5 μg. 
2.6.5 PLO Cell Cytotoxicity with CRACWT 
To measure the protective effect of the CRACWT peptide against PLO, THP-1 cells 
were incubated with protein samples containing (i) PLO, (ii) PLO + CRACWT, or (iii) PLO 
+ CRACSCR.  PLO-containing samples were incubated with cells for 2 hr.  The mass of 
PLO in each sample was 1.6 μg. 
2.7 Peptide Binding Centrifugation Assay 
To measure the binding of the CRACWT and CRACSCR peptides to Chol, a 
centrifugation assay was performed [197].  The peptides (7.0 x 10-5 M) were incubated 
with 100% POPC or 60% POPC/40% Chol liposomes at a lipid-to-protein ratio of 100:1 
for 30 min, then added to a centrifugal filter (Amicon® 30k MWCO, EMD Millipore, 
Billerica, MA) and centrifuged for 1 hr at 6,000 x g [198, 199].  The unbound peptide 
concentrations were determined by comparing the intrinsic fluorescence of the eluate at 
305 nm to a set of standards of the same peptide with known concentrations.  The 
fluorescence measurements were recorded on a Quantamaster® 400 spectrofluorometer 
(PTI Horiba, Edison, NJ) using an excitation wavelength of 281 nm.  The bound peptide 
concentrations were then calculated from the total and free concentrations of peptide. 
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2.8 Peptide Design  
Peptides used in this work were derived from the CRAC domain of LtxA including 
flanking residues (residues 328-346).  CRACWT is the CRAC domain and flanking residues 
with no alterations. Mutant peptides designed in this work are peptides that contain the 
same sequence of residues of CRACWT but have had certain residues mutated (Table 3.2, 
Table 5.1, and Table 6.1). 
2.9 Peptide Synthesis 
The peptides used in this work (Table 3.2, Table 5.1, and Table 6.1) were prepared 
using Fmoc solid-phase synthesis.  Briefly, the Fmoc group of H-Rink Amide ChemMatrix 
resin (0.47 mmol/g) was removed with a solution of 6% piperidine (wt%), 1% 1-
hydroxybenzotriazole monohydrate (HOBt) (wt%) in dimethylformamide (DMF) for 30 
min then washed with methanol (MeOH) and dichloromethane (DCM).  Fmoc-amino acid 
(4.0 equiv.) was coupled with tetramethyl-O-(1H-benzotriazol-1-yl)uronium 
hexafluorophosphate (HBTU) (3.9 equiv.), and N,N-diisopropylethylamine (DIEA) (8.0 
equiv.) in DMF (25 mL) for 90 min followed by washing with MeOH and DCM.  
Subsequent Fmoc groups were removed using the same deprotection and washing steps 
used for the resin, and the progress of the synthesis was periodically verified by matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) 
(Bruker Corporation, Billerica, MA).  At the end of the solid phase synthesis, the N-
terminal amino acid was capped using acetic anhydride with DIEA in DMF for 30 min.  
The peptide was then cleaved from the resin with a solution of 2.5% triisopropylsilane 
(vol%), 2.5% water (vol%), and 95% (vol%) trifluoroacetic acid (TFA) for 2 hr or a 
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solution of 2.5 thioanisole (vol%), 5% phenol (vol%), 5% water (vol%), 2.5% (vol%) 1,2-
ethanedithiol, and 82.5% (vol%) TFA for 3 hr and precipitated with cold diethyl ether. 
2.10 Peptide Purification 
The peptide was purified by reversed-phase high-performance liquid 
chromatography (HPLC) on a Luna prep 10 μm, 250 mm × 21.2 mm C8 column 
(Phenomenex, Torrance, CA) (phase A: water, 0.1% TFA; phase B: acetonitrile, 0.1% 
TFA) using a gradient from 95/5 A/B to 0/100 A/B over 18 min.  The identity of the peptide 
was confirmed with MALDI-TOF MS.  The purified peptide was then lyophilized and 
stored at -80° C. 
2.11 Isothermal Titration Calorimetry 
To investigate the interaction of LtxA with Chol and the interaction of the CRACWT 
peptide with Chol and three additional sterols, isothermal titration calorimetry (ITC) was 
performed.  ITC measurements were performed at 30 °C in a Low Volume Nano ITC 
instrument (TA Instruments, New Castle, DE).  For measurements of LtxA affinity, 50 μL 
of a liposome solution (10 mM) was injected into a cell containing 100 μM LtxA. The 
injected liposome solution was composed of either 100% POPC or 60% POPC and 40% 
Chol.  For measurements of CRACWT affinity, 50 μL of CRACWT (7.65 mM) was injected 
into a cell containing a 2 mM liposome solution, composed of 100% POPC or 60% POPC 
and 40% sterol, where the sterol was Chol, Desmo, DHC, or CC.  A control was also run 
by titrating CRACSCR into liposome solutions of either 100% POPC or 60% POPC and 
40% Chol.  The thermodynamics of each reaction were determined by fitting curves of the 
raw heats to models within NanoAnalyze version 3.5.0.  As shown in Figure 2.2, 
interactions between full-length LtxA or either peptide with 100% POPC membranes were 
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fit using the independent model, in which each protein/peptide can bind to n POPC 
molecules.  Interactions between full-length LtxA or either peptide with membranes 
composed of POPC and sterol were fit using the multiple-sites model, with a ratio of sites 
of 1.5/1, corresponding to a lipid composition of 60% POPC and 40% sterol, where each 
protein/peptide can bind to n POPC molecules and m sterol molecules.  The equations used 
for the fits performed by the independent model and the multiple-sites model utilize 
experimentally known quantities (total sample concentrations and individual heats 
measured) and have been detailed previously [200]. 
2.12 Peptide Structural Changes 
To determine the structure of CRACWT after binding to Chol and other sterols, CD 
spectra were collected using a Jasco J-815 CD spectrometer (Jasco Inc., Easton, MD).  
Spectral scans were performed from 240-190 nm, with a scanning speed of 20 nm/min, a 
bandwidth of 1.0 nm, and in 10 mM phosphate buffer using a peptide concentration of 0.25 
mg/mL.  A 0.01 cm path-length quartz cuvette was used for the measurements.  To ensure 
that the spectra represent the structure of only bound peptide, unbound peptide was 
removed using centrifugal filters (Amicon® 30k MWCO, EMD Millipore, Billerica, MA) 
after 30 min [198, 199].  CD spectra were processed in ORIGIN® PRO 2016 (OriginLab, 
Northampton, MA).  The secondary structure was determined with DICHROWEB using 
CONTIN/LL and either the SP175 references set (for solutions containing only peptide) or 
the SMP180 reference set (for solutions containing peptides and liposomes) [201-206]. 
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Figure 2.2 Isothermal Titration Calorimetry Experiments. 
Types of ITC Experiments Performed.  (A) 10 mM of 100% POPC liposomes were titrated 
into 100 μM of LtxA.  LtxA interacts with one set of n sites (POPC lipid molecules).  (B) 
10 mM of 60% POPC/40% Chol liposomes were titrated into 100 μM of LtxA.  LtxA 
interacts with two sets of n sites (POPC or Chol lipid molecules).  (C) 7.65 mM of CRACWT 
was titrated into 2 mM 100% POPC.  CRACWT interacts with one set of n sites (POPC lipid 
molecules).  (D) 7.65 mM of CRACWT was titrated into 2 mM 60% POPC/40% sterol 
liposomes.  CRACWT interacts with two sets of n sites (POPC or sterol lipid molecules). 
 
2.13 Membrane Packing Assay 
To investigate bilayer packing, a generalized polarization (GP) assay was 
performed.  Laurdan was incorporated into liposomes containing 100% POPC, 80% 
POPC/20% sterol, or 60% DMPC/40% Chol.  The liposomes were then incubated with 
either liposome buffer, CRACWT, or CRACSCR at a lipid to peptide ratio of 50:1, at 23 °C 
for 15 min before the sample was excited at 340 nm using a Quantamaster® 400 
spectrofluorometer (PTI Horiba, Edison, NJ).  The GP was calculated using the following 
equation:  
    𝐺𝑃 =
𝐼440−𝐼490
𝐼440+𝐼490
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where I440 and I490 are the fluorescence emission intensities at 440 nm and 490 nm, 
respectively. 
2.14 Fluorescent LtxA Labeling 
LtxA was labeled with Alexa Fluor® 555 NHS Ester (Molecular Probes, Eugene, 
OR) according to the manufacturer’s instructions, with one modification.  Specifically, 
after LtxA was labeled (AF555-LtxA), it was purified using a 40,000 MWCO Zeba™ Spin 
Desalting column (Pierce Biotechnology, Rockford, IL). 
2.15 Confocal Microscopy 
To stabilize THP-1 cells onto ibiTreat µ-Dishes (Ibidi, Martinsried, Germany), the 
cells were treated in one of two ways.  1) They were either differentiated into tissue-like 
macrophages using cell culture medium supplemented with PMA (100 ng/mL) over 72 
hours and then the cells were incubated with 2 drops/mL NucBlue® Live ReadyProbes® 
reagent (Molecular Probes, Eugene, OR) for 20 min to label the cell nuclei, or 2) the cells 
were adhered onto ibiTreat µ-Dishes by treating the dishes with poly-L-lysine.  Adherence 
of GUVs onto ibiTreat µ-Dishes was facilitated by treating the dishes with poly-L-lysine.   
Each µ-Dish, containing either THP-1 cells or GUVs, was treated with a peptide or 
PBS for 30 min to allow binding of the peptide to occur before LtxA was added.  Next, 
each µ-Dish was incubated with 30 ng of AF555-LtxA for 30 min.  The molar peptide:toxin 
ratio in each dish was 100:1.  Imaging was conducted using a Nikon C2si+ confocal 
microscope equipped with a LU-N4S laser unit and a 60x oil objective (NA = 1.4).  The 
images were processed using Elements v4.3, Nikon’s imaging software suite and Fiji [207]. 
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2.16 CRACWT Long-Term Cell Cytotoxicity Assay 
THP-1 cells obtained from ATCC were maintained at 37 °C under 5% CO2 in RPMI 
1640 medium containing 10% FBS, 0.05 mM 2-mercaptoethanol, and 40 µg/mL (15.9 µM) 
CRACWT peptide, alongside THP-1 cells grown in peptide-free media.  Over a period of 
65 days, cell viability was measured every two to three days using a Trypan blue assay. 
2.17 Localized Surface Plasmon Resonance (LSPR)  
To investigate the kinetics of binding of several peptides to Chol and/or other 
sterols, LSPR measurements were performed at 23 °C using an OpenSPR instrument 
(Nicoya Lifesciences, Kitchener, Canada).  LSPR differs from SPR in that it produces a 
strong resonance absorbance peak that is very sensitive to the local refractive index that is 
surrounding the ligand and thus it measures changes to the peak’s wavelength, whereas 
traditional SPR measures changes the angle of reflection [208].  For measurements of 
peptide affinity, a liposome solution, composed of 100% POPC or 60% POPC/40% Chol, 
was immobilized on a LIP-1 sensor chip (Nicoya Lifesciences).  Next, 100 μL of peptide, 
at varying concentrations, was flowed over the immobilized liposomes.  The kinetics of 
each reaction were determined by fitting the sensograms to models within TraceDrawer 
version 1.6.1.  Reactions of peptide to 100% POPC were fit to a 1:1 binding model and 
reactions of peptide to 60%POPC/40%Chol were fit to 1:2 binding model.  
2.18 Peptide Partitioning Measurements 
Octanol-water partition coefficients were determined using the shake-flask method 
for each peptide.  Vials containing varying volumes of 1-octanol and 18.2 MΩ/cm ultrapure 
water, from a Milli-Q Advantage A10 system, (always totaling 6 mL) were thoroughly 
shaken by hand for 1 min each, then left to stand over a period of 6 hours until both 
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substances had separated, and two distinct layers were observed.  Each peptide was then 
added to the water phase at a final concentration of 40 mg/L and thoroughly shaken once 
more by hand for 1 min each, then left to stand for 6 hours until both substances had 
separated, and two distinct layers were observed.  Serial dilutions of each peptide were 
created, and their fluorescence measured at 305nm using a Quantamaster™ 400 
spectrofluorometer (PTI Horiba, Edison, NJ) to establish a concentration curve.  The 
fluorescence of the water phase from the octanol-water samples was measured at 305 nm.  
Using the following equation, where the volume of water is (𝑉𝑤), the final concentrations 
of peptide in water is (𝐶𝑤
𝑓), the volume of octanol is (𝑉𝑜), the concentrations of peptide in 
octanol is (𝐶𝑜), and the initial concentrations of peptide in water is (𝐶𝑤
𝑖 ): 
𝑉𝑤𝐶𝑤
𝑓 + 𝑉𝑜𝑐𝑡𝐶𝑜𝑐𝑡 = 𝑉𝑤𝐶𝑤
𝑖  
𝐶𝑤
𝑓
 and 𝐶𝑜𝑐𝑡 for the varying volumes were determined.  The octanol-water partition 
coefficient for each volume set was determined by taking the log of Kow from the following 
equation: 
 
𝐾𝑜𝑤 =  
𝐶𝑜𝑐𝑡
𝐶𝑤
𝑓  
and averaged together [209, 210]. 
2.19 Zeta Potential Measurements 
To measure the surface potential of liposomes containing 100%POPC and 60% 
POPC/40% Chol zeta potential measurements were conducted [211].  Measurements were 
performed on a Malvern Zetasizer Nano ZS (Malvern, Westborough MA).  Liposomes 
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hydrated in liposome buffer were subjected to 10 runs each.  The zeta potential was 
calculated as an average from those 10 runs. 
2.20 Hemolysis Assay 
Sheep erythrocytes were purchased from Colorado Serum Company (Denver, CO).  
Erythrocytes were washed and diluted with phosphate buffered saline (PBS) (pH 7.4) to a 
concentration of 2%.  200µL of 2% erythrocytes were pipetted into a 96 well plate.  The 
positive control was treated with 20% Triton X-100, and a negative control was treated 
with PBS.  Cells that were treated with CRACWT were treated 30 min prior to the addition 
of the protein toxin. Once the protein toxin was added (1.6 µg), the 96 well plate was 
incubated at 37 °C and shaken minimally.  The 96 well plate was centrifuged for 5 min at 
500 x g.  100μL of the resulting supernatant of each sample was transferred to another 96 
well plate and the absorbance was measured at 415 nm using an Infinite 200 Pro plate 
reader (Tecan Group Ltd., Männedorf, Switzerland). The background of each reading was 
subtracted using the negative control. All results were normalized to the positive control 
[212]. 
2.21 Statistical Analysis  
Statistical analysis of the data was performed using ORIGIN® PRO 2016.  In cases 
where P > 0.05, no statistically significant difference was reported between the two data 
sets in question. 
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Chapter 3  
Inhibition of LtxA Toxicity by 
Using Cholesterol-Binding Peptides 
3.1 Introduction 
The pathogenicity of A. actinomycetemcomitans is regulated by several virulence 
factors, including LtxA that selectively kills human immune cells, allowing the organism 
to colonize the host [100, 213].  The mechanism by which LtxA kills cells is congruent 
with a wide variety of bacterial protein toxins, whereby target cell recognition initiates a 
multi-step process that culminates in cell death [214-218].  After binding to Chol within 
lipid raft enriched regions of the cell, LtxA triggers collapse of the microvilli on the outer 
surface of the cell and forms depressions on the cell surface followed by cavities in the 
membrane [89, 219-223]. 
In the current work, we have explored the possibility of inhibiting LtxA binding to 
Chol as a means of inhibiting activity.  We found that the interaction between LtxA and 
Chol is highly specific, requiring both an intact CRAC sequence and a specific sterol 
structure, and disruption of this interaction in several different ways is sufficient to inhibit 
LtxA toxicity.  We significantly reduced the ability of LtxA to kill THP-1 utilizing three 
different methods.  First, we inhibited the association of LtxA with Chol in the target cell 
plasma membrane by removing Chol with methyl-β-cyclodextrin (MβCD), then we 
preincubated the toxin with Chol-containing liposomes which prevented the association of 
LtxA with membrane Chol, and lastly, we blocked the ability of LtxA to bind to membrane 
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Chol using a Chol-binding peptide that we designed.  All three methods significantly 
reduced the ability of LtxA to kill THP-1 cells, demonstrating the potential therapeutic use 
of inhibiting the Chol-binding of LtxA to minimize cytotoxicity. 
3.2 Results 
3.2.1 LtxA toxicity is dependent on the presence of Chol 
The association of LtxA with the membrane suggests that the toxin may interact 
with the cell plasma membrane lipids.  Previously, it was found that LtxA must bind to 
Chol on the Jurkat (Jn.9) cell plasma membrane to kill the cells [102].  To investigate 
whether LtxA binding to the THP-1 membrane is likewise regulated by the presence of 
Chol, we extracted Chol from the THP-1 plasma membrane using MβCD and found that 
the toxicity of LtxA was significantly diminished in the absence of Chol (Figure 3.1).  
When the plasma membrane was replenished with Chol, using MβCD followed by MβCD-
Chol, the cells again became susceptible to LtxA, indicating that the interaction of LtxA 
with Chol on the THP-1 plasma membrane is an essential element of the toxin’s mechanism 
of action.  One-way ANOVA followed by a Tukey test indicated that the Chol-dependence 
of LtxA activity is statistically significant (Table 3.1). 
Neither treatment with MβCD nor treatment with MβCD followed by MβCD-Chol 
was toxic over the time course of the experiment (data not shown).  The actual Chol 
concentrations in the cell membrane before and after MβCD treatment was determined 
using an Amplex® Red Cholesterol Assay.  Untreated cells had a Chol concentration of 
112.01 + 1.87 µM, and after treatment with MβCD, the Chol concentration decreased 
67.6% to 36.38 + 1.34 µM.  Replenishment of Chol with MβCD-Chol restored the Chol 
concentration to near original levels, 104.88 + 1.34 µM. 
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Figure 3.1 Cytotoxicity of LtxA after Chol extraction from THP-1 cells. 
The toxicity of LtxA was measured in THP-1 cells as a function of Chol composition. THP-
1 cells were either untreated, treated with methyl-b-cyclodextrin (MβCD) for 15 min to 
extract Chol, or treated with MβCD for 15 min followed by MβCD-Chol for 1 h to replenish 
Chol. Cells with reduced Chol compositions were significantly less susceptible to LtxA 
than were those with wild-type Chol levels. Replenishment of Chol restored susceptibility 
to LtxA. The data represents the average of three independent experiments, and the error 
bars represent the standard deviation. A one-way analysis of variance followed by a Tukey 
test was used to determine the level of significance between each experiment. ***P ≤ 
0.001; N.S., not significant. 
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Table 3.1 Summary of statistical comparisons of data. 
One-way ANOVA using the Tukey comparisons test within ORIGIN® PRO 2016. ***P ≤ 
0.001; **P ≤ 0.01; N.S., not significant. 
 
Comparison P value Significance 
LtxA vs. MβCD + LtxA 0.00008 *** 
LtxA  vs. MβCD + MβCD-Chol + 
LtxA 
0.0724 N.S. 
MβCD + LtxA vs. MβCD + MβCD-Chol + 
LtxA 
0.00003 *** 
LtxA  vs. LtxA + POPC 0.244 N.S. 
LtxA  vs. LtxA + POPC/Chol 0.000004 *** 
LtxA vs. LtxA + POPC/Ergo 0.464 N.S. 
LtxA + POPC  vs. LtxA + POPC/Chol 0.00225 ** 
LtxA + POPC  vs. LtxA + POPC/Ergo 0.983 N.S. 
LtxA + POPC/Chol  vs. LtxA + POPC/Ergo 0.00103 ** 
CRACWT + POPC vs. CRACWT + POPC/Chol 0.00502 ** 
CRACWT + POPC  vs. CRACSCR + POPC/Chol 0.00001 *** 
CRACWT + 
POPC/Chol  
vs. CRACSCR + POPC/Chol 0.00026 *** 
LtxA vs. LtxA + CRACWT 0.000003 *** 
LtxA vs. LtxA + CRACSCR 0.248 N.S. 
LtxA + CRACWT  vs. LtxA + CRACSCR 0.00001 *** 
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3.2.2 Inhibition of binding to Chol inhibits LtxA toxicity 
We investigated the possibility of blocking the binding of LtxA to Chol on the 
target cell plasma membrane as a means to inhibit the toxin’s activity by preincubating the 
toxin with liposomes composed of 60% POPC and 40% Chol.  First, we incubated LtxA 
with Chol-containing liposomes before incubating the mixture with THP-1 cells, with the 
idea that the LtxA would bind to Chol on the liposome and therefore be unable to bind to 
Chol on the cell membrane.  Figure 3.3 demonstrates that this approach was successful.  
THP-1 cells were susceptible to free LtxA; however, when the LtxA was preincubated with 
60% POPC/40% Chol liposomes, the cells remained viable throughout the experiment. 
To determine the specificity of this inhibition, we repeated the experiment using 
two types of liposomes that did not contain Chol, 100% POPC liposomes and 60% 
POPC/40% Ergo liposomes.  Ergo is a sterol found in yeast and other fungal membranes 
that differs in structure from Chol in both the ring and tail domains (Figure 3.2).  As shown 
in Figure 3.3, neither type of liposome was able to inhibit LtxA toxicity.  The additional 
double bonds in the body and tail of Ergo, plus the added methyl group to the tail of Ergo 
demonstrate that these structural changes create an unfavorable binding environment for 
LtxA and interfere with its ability to interact with the membrane.  The decrease in affinity 
for Ergo-containing membranes could be a result of changes to membrane properties, (Ergo 
orders lipid chains more affectively and creates a more rigid bilayer than Chol), inability 
of the CRAC domain to favorably bind to Ergo based on structural differences, or both [19, 
140, 224-227].  This indicates that the interaction between LtxA and Chol is unique and 
suggests that inhibiting the binding of LtxA to Chol could be an effective approach to 
42 
 
prevent LtxA toxicity.  Furthermore, the specificity of this interaction was statistically 
significant as determined by a one-way ANOVA followed by a Tukey test (Table 3.1). 
 
.  
Figure 3.2 Structure of Ergosterol 
Red circles indicate differences versus Chol. 
 
3.2.3 Chol-binding peptides inhibit LtxA toxicity   
We next investigated the possibility of inhibiting LtxA activity using a Chol-
binding peptide derived from the CRAC337 site of LtxA.  A Chol-binding peptide 
(CRACWT), consisting of the CRAC337 sequence of LtxA with six flanking residues on 
either side, and a scrambled control (CRACSCR), in which the CRAC motif was scrambled, 
were synthesized for this purpose.  The sequences of the two peptides are shown in Table 
3.2.  An analytical centrifugation assay was used to demonstrate that the CRACWT peptide 
binds more effectively to liposomes containing 40% Chol than it does to those without 
Chol (Figure 3.4), indicating that this peptide binds to Chol in the liposome.  Additionally, 
the CRACWT peptide bound to a greater extent to the 40% Chol liposomes than did the 
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CRACSCR peptide, demonstrating that, as in the full-length toxin, the intact CRAC 
sequence is essential for this binding.  The results of a statistical analysis of this data are 
included in Table 3.1. 
 
Table 3.2 Sequences of Wild-Type and Scrambled Peptides 
Residues underlined refer to the CRAC domain.  Each peptide was acetylated at the N-
terminus and amidated at the C-terminus. 
 
Peptide Sequence 
CRAC
WT
 FDRARMLEEYSKRFKKFGY 
CRAC
SCR
 FDRARMYEKLERSFKKFGY 
 
This binding experiment was repeated with multiple liposome concentrations and 
the half maximal effective liposome concentration (EC50) of CRAC
WT binding to 
POPC/Chol liposomes was determined using a sigmoidal fit of the data (not shown).  The 
results of this fit predict an EC50 of 3.2 µM, where EC50 represents the concentration of 
liposome solution that will generate a response halfway between the maximum response 
and baseline. 
To inhibit LtxA binding to Chol and the resulting toxicity, we incubated THP-1 
cells with LtxA alone or in combination with the CRACWT peptide or the CRACSCR 
peptide.  As shown in Figure 3.5, the CRACWT peptide, but not the CRACSCR peptide, 
inhibited the activity of LtxA almost completely.  A statistical analysis of these results is 
included in Table 3.1.  Neither peptide was toxic to the cells at the concentrations used 
over the time course of the experiment.   
To determine the half maximal peptide inhibitory concentration (IC50) of the 
CRACWT peptide, the experiment was repeated with several peptide concentrations, and 
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the data was fit to a sigmoidal curve (not shown).  The results of this fit predict an IC50 of 
6.1 µM for the CRACWT peptide and demonstrates that an LtxA-derived Chol- binding 
peptide can be used to specifically alter the binding and subsequent toxicity of LtxA against 
several cell types, suggesting that the approach may have broad applicability in the 
treatment of A. actinomycetemcomitans infections.  The IC50 represents the concentration 
of the peptide where the activity of LtxA is reduced by half. 
 
 
Figure 3.3 Pre-binding to Chol inhibits LtxA toxicity. 
LtxA was preincubated with liposomes composed of 60% POPC and 40% Chol for 15 min 
before incubation with THP-1 cells for a period of 3 hrs.  Preincubation of LtxA with these 
Chol-containing liposomes completely inhibited the toxicity of LtxA.  Preincubation of 
LtxA with liposomes without Chol, composed of either 100% POPC or 60% POPC/40% 
Ergo, did not inhibit LtxA toxicity.  A one-way analysis of variance followed by a Tukey 
test was used to determine the level of significance between each experiment.  ***P ≤ 
0.001; **P ≤ 0.01; N.S., not significant. 
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Figure 3.4 CRACWT peptide has an affinity for Chol. 
A peptide corresponding to the Chol-binding motif in LtxA (CRACWT) was synthesized 
along with a control peptide in which the Chol-binding sequence was scrambled 
(CRACSCR).  The peptides were incubated with liposomes composed of either 100% POPC 
or 60% POPC/40% Chol for 30 min.  Unbound peptide was separated from the liposome–
peptide complexes using a centrifugal filter, and the concentration of unbound peptide was 
determined by comparing the fluorescence intensity of the eluate to a set of standards.  
CRACWT bound significantly more to liposomes containing Chol than to those without 
Chol.  CRACSCR bound with a lower affinity to the POPC/Chol liposomes than did 
CRACWT.  A one-way analysis of variance followed by a Tukey test was used to determine 
the level of significance between each experiment.  ***P ≤ 0.001; **P ≤ 0.01. 
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Figure 3.5 CRACWT peptide inhibits LtxA toxicity. 
LtxA and either CRACWT or CRACSCR were incubated with THP-1 cells for 3 h, and the 
viability of the cells was measured using a trypan blue assay. The CRACWT peptide, which 
binds to Chol, inhibited the toxicity of LtxA, but the CRACSCR peptide, which does not 
bind to Chol, did not inhibit LtxA toxicity. A one-way analysis of variance followed by a 
Tukey test was used to determine the level of significance between each experiment. ***P 
≤ 0.001; N.S., not significant. 
 
3.3 Discussion 
Greater than 90% of cellular Chol resides at the plasma membrane and is essential 
for cell viability and proliferation [124, 228].  Chol is not uniformly dispersed throughout 
biological membranes; rather, it is sequestered in membrane microdomains known as lipid 
rafts, along with sphingolipids and specialized proteins, such as 
glycosylphosphatidylinositol (GPI)-anchored proteins, heterotrimeric G protein-coupled 
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receptors, and Src family kinases [229-233].  Many pathogens and their virulence factors 
have thus developed the ability to recognize and bind to lipid raft Chol on the surface of 
host cells.  For example, Chol is required for the uptake of mycobacteria and Leishmania 
by host cells and allows these intracellular pathogens to avoid degradation by inhibiting 
lysosomal-phagosomal fusion [234-236].  In addition, the activity of several bacterial 
toxins depends on the presence of Chol in the target membrane [102, 135, 138, 221-223, 
237-243].  Influenza, human immunodeficiency virus type 1, and the Ebola virus also 
require Chol in the host membrane for binding to and/or exit from the cell [244-246]. 
In the current study, we used THP-1, a human monocytic leukemia cell line, which 
expresses LFA-1, to investigate the role of Chol binding by LtxA on its toxicity [247].  
While others have shown that LtxA cytotoxicity requires the expression of LFA-1 by the 
host cell, it has also been shown that LtxA is strongly membrane-active and has a 
particularly strong affinity (10-12 M) for membranes containing 40% Chol [89, 101, 248-
250].  This membrane activity is correlated with subtle conformational changes in the entire 
protein structure, but a significant decrease in helicity within the Chol-binding domain 
upon association with Chol.  These conformational changes are what allows the protein to 
move from a water-soluble to a membrane active state [182, 250, 251]. 
To determine the dependence of LtxA on Chol within the membrane, MβCD was 
utilized to remove and replenish Chol content and measure the effectiveness of LtxA in 
killing THP-1 cells in these two environments.  This technique has been implemented 
previously in other studies to determine the effect of Chol in a specific interaction [119, 
252, 253].  We found by removing Chol from the membrane, the cytotoxic ability of LtxA 
towards THP-1 cells was significantly inhibited (Figure 3.1).  This was seen in other 
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pathogens with a dependence on membrane Chol as well, including poliovirus, PFO, and 
the CRAC domain containing cytolethal distending toxin (CDT) [138, 254, 255]. 
From our MβCD results, LtxA was observed to rely significantly on the presence 
of Chol.  To determine if we could utilize LtxA’s dependence on membrane Chol as an 
antivirulence approach to inhibit the toxin’s activity toward THP-1 cells, we synthesized 
Chol-containing liposomes in which LtxA has previously shown to have an affinity for 
[102].  Using LtxA’s strong affinity for Chol-containing liposomes, we introduced a novel 
approach at inhibiting LtxA cytotoxicity that deviates from the traditional role of liposomes 
serving as drug delivery vehicles [256-258].  Preincubating Chol-containing liposomes 
with LtxA prior to the introduction of THP-1 cells resulted in a significant decrease in cell 
cytotoxicity, as shown in Figure 3.3.  LtxA’s strong affinity for Chol within the liposome 
allowed it to bind to the liposomal membrane and stay bound throughout the incubation 
period, thus preventing LtxA from interacting with THP-1 cells.  This type of approach, 
where a synthetic intermediate is used to compete against a host cell for toxin binding, has 
shown to be effective against several bacterial toxins in vitro and in vivo [75, 259].  In one 
case, synthetic liposomes were able to prevent fatalities from occurring in a murine model 
infected with septicemia from S. aureus and Streptococcus pneumoniae [259].  In a second 
case, a synthetic oligosaccharide scaffold was effective in binding to the bacterial toxin 
and preventing it from reaching the host cell, thus inhibiting toxin cytotoxicity in vitro and 
in vivo as well [75].   
To build upon a previous study where CRAC peptides were used to inhibit LtxA 
from binding to Chol-containing liposomes, we investigated the ability of CRAC peptides 
to inhibit LtxA’s ability to bind to THP-1 cells [102].  We found CRACWT can also bind 
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to Chol within the THP-1 cell membrane, thus preventing the binding of LtxA and leading 
to a significant reduction of LtxA cytotoxicity (Figure 3.5).  This study signifies the first-
time a peptide, with an affinity for Chol, has been used to inhibit a pathogen that also has 
an affinity for Chol. 
In conclusion, this work demonstrates the requirement of Chol binding by LtxA in 
cytotoxicity.  Based on this and our previous results, we can conclude that LtxA requires 
Chol within the membrane to be available for binding in order for the toxin to kill the target 
cells. 
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Chapter 4  
Use of a Cholesterol Recognition Amino 
Acid Consensus Peptide to Inhibit Binding 
of a Bacterial Toxin to Cholesterol 
 
4.1 Introduction 
Chol binding is usually the first step in the pathogenic mechanism of toxins or 
viruses as they move from the aqueous extracellular environment to hydrophobic 
membrane environment.  Thus, disruption of this recognition process represents a possible 
method to inhibit bacterial and viral pathogenesis.  Furthermore, we’ve previously 
demonstrated three alternative approaches to inhibit bacterial toxin activity.  In the first we 
found that the removal of Chol from the cell’s plasma membrane significantly reduced the 
toxic ability of the bacterial toxin LtxA by reducing the number of binding locations.  In 
the second approach we demonstrated the use of synthetic vesicles that compete with the 
host cell to bind LtxA.  Lastly in the third approach, we utilized a Chol-binding peptide 
containing a CRAC domain that can bind to Chol on the cell membrane thus preventing 
LtxA from binding and rendering the cell unsusceptible to the toxin’s activity [17, 19].   
Here, our goal was to investigate the interaction between CRACWT and Chol and 
determine the effect this peptide’s interaction has on LtxA’s ability to bind to the 
membrane.  Using several biophysical techniques, we found that CRACWT has a strong 
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affinity for Chol.  In addition, we determined that the hydroxyl group of Chol is key to the 
interaction between CRACWT and Chol.  Furthermore, using confocal microscopy we 
visualized the ability of CRACWT to inhibit toxin binding to synthetic Chol-containing 
membranes.  The ability of CRACWT to prevent membrane binding led to its ability to 
prevent LtxA internalization and subsequent cytotoxicity to THP-1 cells as well.  Through 
these studies, we found that the peptide interacts strongly near the surface of the membrane 
through the recognition of the hydroxyl group of Chol and as a result LtxA is unable to 
recognize and bind Chol, thus demonstrating an alternative approach to prevent the toxin 
from binding to the membrane and then killing the cells. 
4.2 Results 
4.2.1 LtxA and CRACWT have a strong affinity for Chol 
A total of six experiments were performed to investigate the thermodynamics of 
binding of LtxA to POPC and Chol, as well as binding of CRACWT and CRACSCR to POPC 
and Chol.  These experiments were designed to be conducted at a lipid composition at 
which no phase separation is expected, so that the thermodynamic properties of binding to 
Chol could be extracted without the additional complications of phase separation [260-
262]. 
To obtain the thermodynamic properties of binding of LtxA to membranes, 
liposomes composed of either 100% POPC or 60% POPC and 40% Chol were titrated into 
a solution of LtxA, and the data were fit using the independent model or the multiple-
binding sites model, respectively (Figure 2.2).  The heats of injection and the lines of best 
fit are shown in Figure 4.1, and the thermodynamic constants obtained are listed in Table 
4.1.  The equilibrium dissociation constant (KD) of association of LtxA with POPC was 
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determined to be 8.75 × 10−4 M, and its negative entropic value suggests that desolvation 
effects from the hydrophobic interactions between LtxA and POPC dominate the reaction 
[263-265].  The KD for the interaction between LtxA and Chol was determined to be 2.31 
× 10−10 M, which was 6 orders of magnitude more favorable than the affinity of LtxA for 
POPC.  As shown in Table 4.1, the Gibbs free energy (ΔG) of the interaction between LtxA 
and Chol is much more favorable than that between LtxA and POPC.  The entropic (ΔS) 
contribution to ΔG is similar for both reactions, but the enthalpic (ΔH) contribution from 
the binding of LtxA to Chol is much more favorable than that for binding of LtxA to POPC, 
indicating that more and/or stronger noncovalent bonds are formed between LtxA and Chol 
relative to LtxA and POPC [264, 266, 267].   
To determine the thermodynamic properties of binding of CRACWT and CRACSCR 
to Chol, each peptide was individually titrated into a solution of liposomes composed of 
either 100% POPC or 60% POPC and 40% Chol.  The data were fit using the independent 
model or the multiple-binding sites model, respectively (Figure 2.2).  The heats of injection 
and the lines of best fit are shown in Figure 4.2 and Figure 4.3, and the thermodynamic 
constants obtained are listed in Table 4.1.  The results listed in Table 4.1 indicate that the 
CRACWT peptide interacts weakly with membranes composed of 100% POPC, with a 
dissociation constant of 3.81 × 10−4 M.  The affinity of this peptide for membranes 
containing 40% Chol was 5.05 × 10−8 M, four orders of magnitude stronger than the affinity 
of the peptide for POPC.  ΔG is more favorable for binding of CRACWT to Chol than to 
POPC, and like that for LtxA, this difference is due to differences in the enthalpic rather 
than entropic contributions to the free energy.   
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Because the CRACSCR peptide lacks an intact CRAC sequence, we hypothesized 
that this peptide would have minimal affinity for Chol and could therefore be used in this 
work as a negative control.  Using ITC, we found that the affinity of the CRACSCR peptide 
for POPC membranes was reduced relative to that of CRACWT.  In addition, the presence 
of Chol in the membrane did not enhance the affinity of CRACSCR for the membrane (Table 
4.1), demonstrating that this peptide has a significantly reduced affinity for Chol.  
Comparison of the free energy values and affinity constants of LtxA and CRACWT for 
membranes (Table 4.1) indicates that both LtxA and CRACWT have a significantly greater 
affinity for Chol than for POPC.  Furthermore, the similarity between the thermodynamics 
of the interaction of CRACWT and LtxA with Chol suggests that the affinity of LtxA for 
Chol is driven primarily by the toxin’s CRAC motif. 
4.2.2 CRACWT secondary structure is altered upon binding to Chol 
The favorable enthalpy change observed in the ITC experiment upon CRACWT 
binding to Chol indicates that this reaction results in more and/or stronger noncovalent 
bonds between the peptide and Chol than between the peptide and POPC.  To investigate 
whether conformational changes are involved in this difference in binding, we conducted 
a CD experiment. 
The mean residue ellipticity (MRE), which measures the molar CD of each residue 
within the peptide, was calculated for each CD spectrum (Figure 4.4).  The MRE was 
measured for CRACWT in solution and after CRACWT interacted with membranes 
composed of 100% POPC or 60% POPC/40% Chol (Figure 4.5).  Initially, CRACWT in 
solution is roughly composed of 25% α-helices and 25% β-sheets with the remaining 
structure containing random coils and being unordered.  Similarly, other CRAC peptides 
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of similar length including molecular dynamics simulations of CRACWT have produced 
comparable solution structures to CRACWT [182, 268]. 
As the peptide moved from solution to a POPC membrane, the helicity decreased 
slightly, and the fraction of β-sheet structure increases slightly.  The structural changes as 
the peptide moved from solution to a Chol-containing membrane were much more 
pronounced, with a large decrease in helicity and a large increase in β-sheet structure, 
indicating that at least some of the differences in the enthalpic contributions to free energy 
observed by ITC are due to conformational changes in the peptide upon binding to Chol. 
4.2.3 CRACWT membrane affinity depends on sterol structure 
To characterize recognition by CRACWT of Chol in the membrane, we performed 
ITC experiments using liposomes composed of POPC and one of four sterols.  As shown 
in Figure 4.7, each sterol varied only slightly in structure from that of Chol, allowing us to 
determine if CRACWT recognition of the sterol occurs at the head, body, or tail of the 
molecule.  Relative to Chol, Desmo, has an altered tail, DHC has an altered A ring, and CC 
has an altered headgroup.  The results, shown in Figure 4.6 and Table 4.2, indicate that 
CRACWT has the lowest affinity (6.86 × 10−2 M) for liposomes containing CC, which has 
a modified headgroup, followed by liposomes containing Desmo (2.39 × 10−4 M), which 
has a modified tail relative to that of Chol.  Slightly reduced affinity, relative to Chol, was 
measured for liposomes containing DHC (2.53 × 10−7 M), which has a modified ring 
structure relative to that of Chol.  These results suggest that the recognition of Chol by 
CRACWT occurs primarily at the hydroxyl group and hydrocarbon groups of Chol. 
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Figure 4.1 Raw ITC Heats of Injection for LtxA and POPC, POPC/Chol. 
ITC measurements were performed at 30 °C in a Low Volume Nano ITC.  50 μL of a 
liposome solution (10 mM) was injected into a cell containing 100 μM LtxA.  Triangles 
depict each 1 µL injection of 100% POPC titrated into LtxA.  Circles depict each 1 µL 
injection of 60% POPC/40% Chol titrated into LtxA.  Lines of best fit are shown, with long 
dashes depicting POPC/Chol and short dashes depicting POPC. 
 
Table 4.1 Thermodynamics of the Interactions of LtxA and CRACWT with Chol. 
Liposomes composed of 100% POPC or 60% POPC/40% Chol were titrated into a solution 
containing either LtxA or CRACWT.  The affinity and thermodynamic properties were 
obtained using one of two models, as described in the Methods section. 
 KD 
(M) 
ΔH 
(kJ/mol) 
-TΔS 
(kJ/mol) 
ΔG 
(kJ/mol) 
LtxA + POPC 8.75 x 10-4 ± 2.40× 10−5 15.24 -32.99 -17.8 
LtxA + Chol 2.31 x 10-10 ± 9.80× 10−11 -29.76 -26.15 -55.9 
CRACWT + POPC 3.81 x 10-3 ± 2.13× 10−3 32.58 -46.8 -14.2 
CRACWT + Chol 5.05 x 10-8 ± 3.47× 10−3 2.81 -46.2 -43.4 
CRACSCR + POPC 5.36 x 10-5 ± 2.25× 10−5 −7.65 −17.27 −24.9 
CRACSCR + Chol 4.07 x 10-4 ± 4.13× 10−5 −5.45 −14.24 −19.7 
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To verify that the observed inhibition of CRACWT binding in the presence of 
Desmo, CC, and DHC, relative to that with Chol, is due specifically to changes in sterol 
structure and not a decrease in membrane fluidity that could prevent peptide association, a 
GP experiment was performed.  Using POPC liposomes containing Laurdan, a fluorescent 
molecule that is sensitive to the presence of water within the membrane, we measured the 
GP of membranes composed entirely of POPC or of POPC and one of the four sterols 
[269].  As shown in Figure 4.7B, Chol significantly decreased fluidity in the membrane 
relative to that of 100% POPC, measured by an increase in GP, as expected.  Both DHC 
and Desmo decreased the fluidity similar to Chol.  CC decreased the fluidity of the POPC 
membrane slightly, but much less so than Chol, DHC, or Desmo.  This result indicates that 
the reduction in the level of binding observed in the ITC experiments is due to sterol 
structure and not overly tight packing of the membrane. 
4.2.4 CRACWT does not disrupt membrane packing 
To determine if CRACWT perturbs bilayer packing in its interaction with the 
membrane, another Laurdan fluorescence experiment was performed.  Using Laurdan- 
labeled liposomes of varying compositions, we calculated the GP before and after peptide 
addition, to measure water penetration into the membrane core, as a measure of bilayer 
disruption by the peptide.  Figure 4.7B shows the GP of the membrane in the presence of 
CRACWT or CRACSCR normalized by the membrane’s GP value in the absence of peptide.  
No statistical difference between the GP profiles of any of the membranes in the presence 
or absence of either CRACWT or CRACSCR was found.  This result indicates that neither 
peptide induces water penetration into the hydrophobic core of the membrane, suggesting 
that the peptides do not penetrate deeply into the membrane. 
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Figure 4.2 Raw ITC Heats of Injection for CRACWT and POPC, POPC/Chol. 
ITC measurements were performed at 30 °C in a Low Volume Nano ITC.  50 μL of 
CRACWT (7.65 mM) was injected into a cell containing 2 mM liposome solution.  Inverted 
triangles depict each 2.5 µL injection of CRACWT titrated into 100% POPC.  Squares depict 
each 2.5 µL injection of CRACWT titrated into 60% POPC/40% Chol.  Lines of best fit are 
shown, with long dashes depicting POPC/Chol and short dashes depicting POPC. 
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Figure 4.3 Raw ITC Heats of Injection for CRACSCR and POPC, POPC/Chol. 
ITC measurements were performed at 30 °C in a Low Volume Nano ITC.  50 μL of 
CRACSCR (7.65 mM) was injected into a cell containing 2 mM liposome solution.  Squares 
depict each 2.5 µL injection of CRACSCR titrated into 100% POPC.  Circles depict each 
2.5 µL injection of CRACSCR titrated into 60% POPC/40% Chol.  Lines of best fit are 
shown, with short dashes depicting POPC/Chol and long dashes depicting POPC. 
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Figure 4.4 MRE CD Spectroscopy Data of CRACWT. 
Spectral scans were performed in 10 mM phosphate buffer, using a peptide concentration 
of 0.25 mg/mL. To ensure that the spectra represent the structure of only bound peptide, 
unbound peptide was removed using centrifugal filters. MRE was calculated for each 
spectrum. Filled in squares depict spectrum of CRACWT in solution. Filled in triangles 
depict spectrum of CRACWT in 100% POPC. Filled in circles depict spectrum of CRACWT 
in 60% POPC/40% Chol. Empty squares depict spectrum of CRACWT in 60% POPC/40% 
Desmo. Empty circles depict spectrum of CRACWT in 60% POPC/40% DHC. Empty 
triangles depict spectrum of CRACWT in 60% POPC/40% CC. 
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4.2.5 CRACWT peptides inhibit LtxA internalization 
Previously, we showed that CRACWT is able to inhibit LtxA activity in target cells, 
and here, we have demonstrated that the peptide has a strong affinity for Chol [17].  We 
therefore investigated the hypothesis that the peptide inhibits LtxA activity by preventing 
the toxin from binding to Chol and being subsequently internalized by the cell.  To visually 
confirm the affinity of LtxA for Chol we performed a confocal imaging experiment using 
GUVs composed of DOPC/DPPC/Chol (1:1:1).  The GUVs were labeled with the 
fluorescent probe NBD-PE.  As shown in Figure 4.8A, AF555-LtxA was able to bind to 
the GUVs.  When the GUVs were preincubated with CRACWT (Figure 4.8B), LtxA was 
unable to bind to the membranes, indicating that the peptide does block the ability of LtxA 
to bind Chol.  The scrambled peptide, CRACSCR, had no effect on LtxA binding to the 
membranes (Figure 4.8C).  Quantification of the total LtxA intensity is shown in Figure 
4.8D. 
In addition to Chol binding, LtxA must also recognize and bind a cell surface 
receptor, LFA-1 [247, 249, 270].  We therefore investigated whether CRACWT mediated 
inhibition of LtxA binding to Chol is sufficient to inhibit LtxA internalization into target 
cells.  When AF555-LtxA was incubated for 30 min with THP-1 cells in the absence of 
CRAC peptide, internalization of the toxin into THP-1 cells was observed, as shown in 
Figure 4.9A.  In contrast, significantly less AF555-LtxA was detected inside the cells when 
the same amount of the AF555-LtxA was incubated with THP-1 cells pretreated with 
CRACWT, as shown in Figure 4.9A, demonstrating that CRACWT mediated inhibition of 
AF555-LtxA binding to Chol prevents the toxin from being internalized.  THP-1 cells 
pretreated with CRACSCR, the control peptide, did not inhibit AF555-LtxA activity, as 
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shown in Figure 4.9A.  Quantification of the total AF555-LtxA intensity is shown in Figure 
4.9B. 
 
 
Figure 4.5 Predicted secondary structure of CRACWT in solution or in membranes 
composed of 100% POPC or 60% POPC/40% Chol. 
As the CRACWT peptide transitions from a membrane free environment, to a Chol-free 
membrane environment, and lastly to an environment with Chol-containing membranes, 
the helical structure of CRACWT decreases and the sheet structure of CRACWT increases.  
Results were obtained with DICHROWEB using CONTIN/LL and either the SP175 or the 
SMP180 reference set.  The bar graph is split into an α-helical structure section (left) and 
a β-sheet structure section (right).  Each bar graph represents data averaged over three 
independent experiments.  The level of significance was determined using an unpaired two-
sample t-test.  ***P ≤ 0.001; **P ≤ 0.01; *P ≤ 0.05; N.S. P > 0.05. 
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Figure 4.6 Raw ITC Heats of Injection for CRACWT and POPC/DHC, POPC/Desmo, and 
POPC/CC. 
ITC measurements were performed at 30 °C in a Low Volume Nano ITC.  50 μL of 
CRACWT (7.65 mM) was injected into a cell containing 2 mM liposome solution.  Triangles 
depict each 2.5 µL injection of CRACWT titrated into 60% POPC/40% DHC.  Squares 
depict each 2.5 µL injection of CRACWT titrated into 60% POPC/40% Desmo.  Diamonds 
depict each 2.5 µL injection of CRACWT titrated into 60% POPC/40% Desmo.  Lines of 
best fit are shown, with short dashes depicting POPC/DHC, long dashes depicting 
POPC/Desmo, and combined long and short dashes depicting POPC/CC. 
 
4.2.6 CRACWT does not exhibit long-term toxicity to cells 
To determine if the CRACWT peptide is toxic to cells over a period of time, which 
would prevent its future therapeutic use, we conducted a long-term viability study.  THP-
1 cells were cultured in media containing 40 μg/mL (15.9 µM) peptide of CRACWT 
alongside THP-1 cells grown in peptide-free media.  Over a period of 65 days, no peptide-
mediated toxicity was observed in the cells, as shown in Figure 4.10, suggesting that this 
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peptide may represent a non-toxic method for blocking bacterial toxin and pathogen 
binding to Chol in host cells.  Furthermore, the concentration used in the long term toxicity 
assay is five times greater than the half maximal effective concentration (EC50) found 
previously for CRACWT and liposomes composed of 60% POPC/40% Chol [17]. 
 
 
 
Table 4.2 Thermodynamic Parameters of the CRACWT Interactions with sterols and 
CRACSCR Interaction with Chol 
Liposomes composed of 100% POPC or 60% POPC/40% sterol were titrated into a 
solution containing either CRACWT or CRACSCR.  The affinity and thermodynamic 
properties were obtained using one of two models, as described in the Methods section. 
 KD 
(M) 
ΔH 
(kJ/mol) 
-TΔS 
(kJ/mol) 
ΔG 
(kJ/mol) 
CRACWT + POPC 3.81 x 10-3 ± 2.13× 10-3 32.58 -46.8 -14.2 
CRACWT + Chol 5.05 x 10-8 ± 3.47× 10-3 2.81 -46.2 -43.4 
CRACWT + Desmo 2.39 x 10-4 ± 8.21× 10-5 1.508 -22.42 -20.9 
CRACWT + DHC 2.53 x 10-7 ± 4.24× 10-8 2.66 -40.91 -38.3 
CRACWT + CC 6.86 x 10-2 ± 1.01× 10-2 -0.80 -5.76 -4.96 
CRACSCR + POPC 5.36 x 10-5 ± 2.25× 10-5 -7.65 -17.27 -24.9 
CRACSCR + Chol 4.07 x 10-4 ± 4.13× 10-5 -5.45 -14.24 -19.7 
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Figure 4.7 Structures of the sterols, Chol, DHC, Desmo, and CC, used in this work and 
the quantification of membrane packing effect from the GP values of Laurdan. 
(A) The structural differences in each sterol relative to Chol are circled.  (B) Laurdan was 
incorporated into liposomes containing 100% POPC, or 80% POPC/20% sterol at 23 °C.  
The fluidity of each membrane was quantified by the GP value of Laurdan, with a lower 
GP indicating a more fluid membrane.  This graph represents data averaged over six 
independent experiments.  (C) Laurdan was incorporated into liposomes containing 100% 
POPC, 80% POPC/20% sterol, or 60% DMPC/40% Chol at 23 °C.  Disruption of bilayer 
packing after peptide incorporation was quantified by the GP value of Laurdan, with a 
lower GP value indicating the presence of water in the membrane core.  Each GP value 
was normalized with respect to the GP value of the specified membrane in the absence of 
peptide.  This graph represents data averaged over three independent experiments.  The 
level of significance for both figures was determined using an unpaired two-sample t-test.  
****P ≤ 0.0001; ***P ≤ 0.001; **P ≤ 0.01; N.S. P > 0.05. 
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Figure 4.8 Peptide-mediated inhibition of LtxA binding to Chol in GUVs. 
GUVs were composed of DOPC/DPPC/Chol (1:1:1), labeled with NBD-PE (green).  (A) 
In the absence of peptide, AF555-LtxA (red) binds to the membrane.  In the presence of 
CRACWT at a peptide:toxin ratio of 100:1, LtxA was inhibited from binding to the 
membrane.  In the presence of CRACSCR at a peptide:toxin ratio of 100:1, LtxA was able 
to bind to the GUV membrane.  The scale bar in the bottom right corner of each micrograph 
represents 10 µm.  (B) Region of interest (ROI) analysis was performed to measure the 
fluorescence intensity of LtxA in the confocal images.  The bar graph represents data 
averaged over 5 independent GUV image captures for each of the three conditions.  The 
level of significance was determined using an unpaired two-sample t-test.  *P ≤ 0.05. 
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Figure 4.9 Peptide-mediated inhibition of LtxA internalization in THP-1 cells. 
THP-1 cells were differentiated into tissue-like macrophages, and the nuclei were labeled 
with NucBlue® Live ReadyProbes® reagent (Thermo Fisher Scientific, blue).  (A) In the 
absence of peptide, AF555-LtxA (red) is located within THP-1 cells.  When the cells were 
preincubated with CRACWT for 30 min at a peptide:toxin ratio of 100:1, AF555-LtxA was 
unable to be internalized by the cells.  Preincubation of the cells with CRACSCR for 30 min 
at a peptide:toxin ratio of 100:1 did not inhibit AF555-LtxA internalization.  The scale bar 
in the bottom right corner of each micrograph represents 10 µm.  (B) Region of interest 
(ROI) analysis was performed to measure the fluorescence intensity of LtxA.  The bar 
graph represents data averaged over every cell for each image captured, for each of the 
three conditions (images were enlarged for clarity and not every cell measured is shown).  
****P ≤ 0.0001. 
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Figure 4.10 Long-term Effect of CRACWT on THP-1 Cell Viability 
THP-1 cells (5 x 105 cell/mL) were grown in medium supplemented with 40 µg/mL 
CRACWT or in the absence of peptide.  Cell viability was measured using a Trypan blue 
assay. 
 
4.3 Discussion 
Treatment of bacterial illnesses has become increasingly difficult as the number of 
antibiotic-resistant organisms increases, and the development of new antibiotics slows to 
record low numbers.  In the last two years, both the CDC and World Health Organization 
(WHO) have issued recommendations for battling the issue of antibiotic resistance, which 
include preventing infections from occurring, improved tracking of resistant organisms, 
more conscientious use of current antibiotics, and the development of new antibiotic 
strategies [3, 5]. 
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In this work, we have demonstrated the effective use of a Chol-binding peptide to 
inhibit the activity of a bacterial toxin, LtxA, a strategy that represents a novel antivirulence 
approach that has broad potential for the treatment of bacterial illnesses.  We demonstrated 
that the CRACWT peptide has a strong affinity for Chol and resides near the membrane 
surface, where it blocks toxin recognition of Chol to inhibit membrane binding and 
subsequent internalization and activity of the toxin.  Importantly, the peptide exhibits no 
long-term toxicity to the cells. 
In considering the use of this peptide to inhibit toxin activity, we considered two 
essential components: (1) localization at the membrane interface to reduce negative 
interactions with essential membrane components, which may lead to cytotoxicity and (2) 
strong binding energetics to outcompete binding by a toxin with a reported strong 
interaction with Chol [102].  A previous molecular dynamics study suggested that the 
CRACWT peptide interacts with the membrane interface but not the core, and investigation 
of the amino acid sequence suggested that the peptide would reside in a location where it 
could interact with both aqueous solution and the membrane environment [182].  A 
snapshot from this molecular dynamics study displays the trajectories of CRACWT 
interacting with PC/Chol membranes (Figure 4.11).  In this figure the central tyrosine, 
shown in green, is seen to be interacting with Chol (magenta) within the membrane. 
Previously, we have demonstrated that a peptide corresponding to the CRAC motif 
in LtxA is able to outcompete the binding of the toxin for Chol and inhibit activity, 
suggesting that the peptide itself has a strong affinity for Chol [17].  We therefore 
undertook this work to demonstrate that our hypotheses were correct and to establish the 
potential use of this peptide in the inhibition of Chol-binding by a range of pathogens.   
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To determine the membrane location of the CRACWT peptide, we used Laurdan 
fluorescence to demonstrate that the peptide does not disrupt membrane packing, 
suggesting that the peptide sits near the interface of the membrane rather than deep in the 
hydrophobic core.  In addition, we found that replacement of the hydroxyl group of Chol 
significantly decreases binding of the peptide, while substitutions to the B ring or 
hydrocarbon chains have smaller effects on binding, indicating that recognition of Chol by 
the peptide occurs near the membrane surface.  These findings are consistent with previous 
findings regarding the CRAC motif found in the fusion protein, gp41, of HIV-1, LWYIK.  
A nearest neighbor recognition (NNR) study demonstrated that the peptide is sensitive to 
the packing of the bilayer, suggesting that the peptide must at least partially penetrate into 
the membrane [271].  However, a molecular simulation experiment of the same peptide, 
along with some derivatives, demonstrated that the peptides prefer the membrane interface 
over the membrane core and interact with the hydroxyl group of Chol electrostatically 
[172].  Magic-angle spinning nuclear magnetic resonance (MAS-NMR) demonstrated, in 
Chol-containing membranes, that the peptide interacts with the A ring of Chol, near the 
membrane interface as well [272]. 
Recognition of the hydroxyl group of Chol may be conserved among pathogens, as 
it would be the first structural element of Chol they encounter upon interaction with a host 
cell membrane.  For example, although they do not use a CRAC motif to recognize Chol, 
the CDCs produced by Gram positive bacteria likewise require the presence of a sterol with 
an intact hydroxyl group; variation in this region completely inhibits activity of the toxins, 
while changes in the ring structure of the sterol reduce activity slightly, and changes to the 
hydrocarbon tail have no effect on toxin activity [150].  In the case of CRACWT (Table 
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4.2), similar requirements can be found when compared to CDCs.  CRACWT also requires 
the presence of a hydroxyl group for binding.  Changes to the ring structure result in slight 
reduction in affinity as well, but the key difference lie in the intact hydrocarbon tail and 
hydroxyl group of Chol.  For CRACWT, changes to the hydrocarbon tail of Chol result in a 
reduced affinity for the sterol, which is not the case for CDCs as no effect is seen with that 
change. 
 
 
Figure 4.11 A Molecular Dynamics Snapshot of CRACWT Interacting with a PC/Chol 
Membrane. 
An interaction can be visualized between Tyr337 residue (green) and the membrane that is 
composed of PC carbons (cyan) and Chol (magenta) [182].  The Phenylalanine residue is 
show in blue and the terminal Tyr is shown in red. 
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In addition to localization at the membrane interface, we hypothesized that strong 
affinity for Chol would be required for the peptide to efficiently outcompete binding to 
Chol by pathogens with reported affinity for Chol.  For this reason, we investigated the 
CRACWT peptide of LtxA.  Previously, it was shown that LtxA has a very strong affinity, 
on the order of 10-12 M, for liposomes containing 40% Chol [102].  Here, we have shown 
that much of the affinity of LtxA for Chol is driven by the CRAC motif, as the peptide 
alone has a comparable affinity for Chol as the full-length protein.  The affinity of the 
CRACWT peptide is several orders of magnitude stronger than reported affinities of PLO 
(4 x 10-7 M), Cdt produced by A. actinomycetemcomitans (2 x 10-6) , α-hemolysin (HlyA) 
produced by Escherichia coli (1.6 x 10-5) , and the invasion plasmid antigen B (ipaB) 
produced by Shigella flexneri (1.8 x 10-5), suggesting that the peptide may be able to 
outcompete binding of these and other pathogenic proteins [273-276]. 
Because many pathogens recognize Chol in their activity against host cells, we 
investigated the ability of a peptide to inhibit protein toxicity by binding to Chol at the 
membrane surface.  We predicted that a CRAC peptide that binds Chol at the membrane 
surface would be able to block the pathogen’s recognition of Chol.  Our results here 
represent proof-of-concept of this idea and we expect that this peptide will have broad 
applications for the treatment of viral and bacterial diseases, as there are currently no viable 
approaches to inhibit this interaction.  Previously proposed strategies include 
cyclodextrins, which have a strong affinity for Chol and are able to extract the sterol from 
the membrane [277].  This molecule has been shown to extract Chol from HIV-1 and SIV-
1 virions, resulting in decreased infectivity and was therefore proposed as a possible topical 
microbicide [278].  In addition, β-cyclodextrins have been proposed for the treatment of 
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intracellular Leishmania infections; however, due to cyclodextrins’ alteration of cell 
processes and viability, this therapeutic use is limited [235].  Here, we have demonstrated 
that the CRACWT peptide, perhaps because its interaction with Chol occurs only near the 
membrane interface, does not induce cytotoxicity in host cells (Figure 4.10).  The ability 
of the CRACWT peptide to inhibit toxin activity by blocking its interaction with Chol in the 
host cell plasma membrane is a novel concept that has wide-ranging applications in 
bacterial and viral pathogenesis. 
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Chapter 5  
Role of Peptide Net Charge on the Affinity of 
a Cholesterol Recognition Amino Acid 
Consensus Peptide for Membrane Cholesterol  
 
5.1 Introduction 
A major problem that we face in creating a potential therapeutic utilizing a CRAC 
domain is that the CRAC definition is not well defined.  It over predicts Chol binding, 
making this domain difficult to study [102, 148, 151].  In the present work, we look to 
improve the binding of CRACWT to the membrane and refine the current CRAC definition.  
We hypothesize that by decreasing the net charge of the CRACWT peptide we would 
increase peptide partitioning into the hydrophobic membrane thus increasing affinity, 
while increasing the net charge would lead to an opposite effect.   
To investigate the effect of net charge on a CRAC peptide’s affinity for membrane 
Chol, we engineered four peptides, derived from our wild-type CRACWT peptide, with a 
varying degree of net charge.  Net charges were altered by substituting Lys and/or Arg for 
a glutamate (Glu), or a Glu for a Lys (Table 5.1).  To determine the effect of these 
substitutions we measured the peptide’s affinities for Chol as well as their ability inhibit 
our model protein toxin’s (LtxA) cytotoxicity to leukocytes utilizing LSPR and cell-based 
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assays respectively.  We found that changes to the net charge of CRACWT led to a decrease 
in the peptide’s affinity for Chol and its ability to inhibit LtxA activity. 
5.2 Results 
5.2.1 Peptide Design 
Peptides used in this study were derived from the CRAC domain of LtxA, including 
residues that surround the domain.  As shown in Table 5.1, CRACWT, is the CRAC domain 
including surrounding residues and is composed of LtxA residues 328-346 (Figure 1.3).  
CRAC-1D, CRAC-1F, CRAC-7, and CRAC+7 are peptides that contained the same residues 
as CRACWT but have had certain residues substituted.  The residues that have been 
substituted are depicted in red as shown in Table 5.1.  The superscript of these four peptides 
denotes their overall net charge. 
Two classes of peptides were synthesized for this study, polyelectrolytes and 
polyampholytes as shown in Figure 5.1.  Polyelectrolytes which are classified as peptides 
composed by mostly positive or negatively charged residues, indicated by the orange or 
blue regions respectively (Figure 5.1), include peptides CRAC+7 and CRAC-7. 
Polyampholytes contain both positively and negatively charged residues, as indicated by 
the green region in Figure 5.1.  This group of peptides include CRAC-1F, CRAC-1D, and 
CRACWT. 
5.2.2 Highly charged peptides favor a hydrophilic environment 
To determine the tendency of each peptide to partition into a hydrophobic 
environment versus a hydrophilic environment we performed an octanol-water experiment 
to measure each peptide’s octanol-water coefficient (log Kow).  CRAC-7
 
and CRAC+7, 
classified as polyelectrolytes, have the highest overall net charge (Figure 5.1), and 
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displayed the greatest partitioning into the hydrophilic environment, as indicated by the 
lowest log Kow coefficient (Figure 5.3).  CRAC
-1D and CRAC-1F, which are classified as 
polyampholytes, and have the lowest overall net charge (Figure 5.1), displayed the greatest 
partitioning into the hydrophobic environment, as indicated by the highest log Kow 
coefficients (Figure 5.3).  CRACWT, also a polyelectrolyte, displayed a log Kow between 
CRAC-7/CRAC+7 and CRAC-1D/CRAC-1F which correlates with it having a net charge 
between the two groups of peptides mentioned. 
Table 5.1 Peptide Sequences of Peptide mutants 
Residues underlined refer to the CRAC domain.  Residues highlighted in red and bolded 
are the residues we mutated from CRACWT peptide.  Each peptide was acetylated at the 
N-terminus and amidated at the C-terminus. 
Peptide Sequence 
CRACWT FDRARMLEEYSKRFKKFGY 
CRAC-1D FDRARMLEEYSERFEKFGY 
CRAC-1F FDEAEMLEEYSKRFKKFGY 
CRAC-7 FDEAEMLEEYSEEFEKFGY 
CRAC+7 FDRARMLKKYSKRFKKFGY 
 
5.2.3 Highly charged peptides have a reduced affinity for the membrane 
To determine the affinity of each peptide for membranes composed of 100% POPC 
and membranes composed of 60% POPC/40% Chol we performed an LSPR experiment, 
as shown in Table 5.2 and Table 5.3 respectively.  CRAC-1D
 
and CRAC-1F, which are 
classified as polyampholytes along with CRACWT (Figure 5.1) have affinities (KD (M)) for 
Chol-containing membranes that were measured to be 6.84 x 10-7
 
M and 3.37 x 10-7
 
M 
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respectively (Table 5.3), which are comparable to CRACWT.  CRAC-7
 
and CRAC+7, which 
are polyelectrolytes (Figure 5.1), with KD values of 1.21 x 10
-4 M and 1.47 x 10-6 M, 
respectively, have a weaker affinity for Chol compared to CRACWT, CRAC-1D
 
and 
CRAC-1F (Table 5.3), but this difference is not statistically significant.  CRAC+7 though 
having a weaker affinity for Chol compared to CRACWT, CRAC-1D
 
and CRAC-1F, has an 
affinity for Chol that is one hundred times stronger than that of CRAC-7.  Zeta potential 
measurements performed on 100% POPC and 60% POPC/40% Chol liposomes, suggest 
that the increased affinity of CRAC+7 to Chol containing membranes arises from 
electrostatic interactions.  Introducing Chol into liposomes decreases the liposomes’ zeta 
potential, shifting it from an overall positive charge to an overall negative charge (Figure 
5.2), thus leading to a more favorable interaction between the negatively charged liposome 
surface and the positively charged peptide.  We hypothesize that this peptide may associate 
with the surface of the liposome through this electrostatic interaction without necessarily 
interacting with membrane cholesterol. 
5.2.4 Structural changes do not correlate with increased membrane affinity 
CD spectroscopy measurements for the peptides were performed in solution, with 
liposomes composed of 100% POPC, and with liposomes composed of 60% POPC/40% 
Chol and are shown in Figure 5.4, Figure 5.5, and Figure 5.6.  Furthermore, CD spectra of 
each peptide in each environment were consolidated and are shown in Figure 5.7. 
CRACWT exhibits typical α-helical characteristics in solution and in 100% POPC 
membranes, with a maximum at 195 nm and a double minima at 208 nm and 222 nm [279].  
In 60% POPC/40% Chol membranes the minima and maximum of CRACWT increase, 
suggesting a decrease of α-helical structure that we have shown previously [19].  Changes 
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to the spectrum of CRAC-1F suggests it transitions from an unordered state in solution to a 
state with increased α-helical structure, containing a double minima at 208 nm and 222 nm. 
 
 
Figure 5.1 Peptide Charge Distribution. 
Polyelectrolytes are classified as peptides that are composed by mostly positive or 
negatively charged residues, indicated by the orange or blue regions respectively.  These 
groups include CRAC+7 and CRAC-7.  Polyampholytes contain both positively and 
negatively charged residues, indicated by the green region. This group includes CRAC-1F, 
CRAC-1D, and CRACWT [280]. 
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In the case of CRACWT and CRAC-1F conformational changes are correlated with 
an increase in affinity for Chol-containing membranes as seen in Table 5.3.  On the other 
hand, CRAC-1D undergoes minimal conformational changes while transitioning from an 
environment of 100% POPC liposomes to an environment containing 60% POPC/40% 
Chol liposomes (Figure 5.7) but exhibits a stronger affinity for 60% POPC/40% Chol 
liposomes versus 100% POPC liposomes (Table 5.3 and Table 5.2 respectively).  This 
suggests that affinity for Chol is not necessarily correlated with conformational changes 
with the peptide. 
For the peptides CRAC-7 and CRAC+7, the MRE data (Figure 5.4, Figure 5.5, 
Figure 5.6, and Figure 5.7) suggests that they occupy a random coil structure in each 
condition with the most noticeable differences occurring when each peptide is interacting 
with 60% POPC/40% Chol membranes.  The maximum at 195 nm for CRAC+7 is more 
positive than CRAC-7, suggesting a more pronounced α-helical structure for CRAC+7. 
5.2.5 CRAC mutants display decreased ability to inhibit LtxA internalization and 
cytotoxicity 
To measure the ability of each CRAC mutant to inhibit LtxA binding to Chol-
containing GUV membranes, we used confocal microscopy to visualize the differences in 
the association of AF555-LtxA to NBD-labeled GUVs.  We found that CRAC-1D
 
and 
CRAC-1F, which have reduced affinities to Chol as CRACWT, were the only peptides that 
could prevent a majority of LtxA from binding to GUVs, as indicated by the reduced red 
intensity associated with the GUVs compared to the control (Figure 5.9).  The moderate 
amount of binding affinity displayed by CRAC+7 for Chol,  which Figure 5.2 suggests to 
be a result of electrostatic interactions, had no significant effect on inhibiting LtxA binding 
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and internalization as indicated by the colocalized toxin (red) and membrane (green) in 
Figure 5.9.  This finding is consistent with our hypothesis that this peptide associates with 
the membrane through electrostatic interactions but does not fully interact with cholesterol.  
Furthermore, CRAC-7 displayed the weakest affinity for Chol and was unable to prevent 
LtxA binding and internalization. 
To determine if inhibition of LtxA binding to Chol by the peptides could prevent 
toxin internalization in cells, we performed a confocal experiment, in which THP-1 cells 
were pretreated with each peptide for 30 min before the mixture was incubated with 
AF555-LtxA, as shown in Figure 5.9.  CRAC-1D
 
and CRAC-1F were able to inhibit LtxA 
internalization, as indicated by the very low number of red pixels inside of the cells.  
Peptides CRAC-7
 
and CRAC+7
 
failed to prevent LtxA internalization, as indicated by the 
large number of red pixels present within the THP-1 cells that they were incubated with 
(Figure 5.9).  The ability of these peptides to inhibit LtxA binding to Chol in GUVs 
correlates with their ability to inhibit LtxA activity in THP-1 cells. 
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Table 5.2 Affinity of Peptides for 100% POPC Liposomes Measured by LSPR 
Reaction KD (M) 
CRACWT binding to POPC 2.38 x 10-5 ± 2.04 x 10-6 
CRAC-1D binding to POPC 3.17x 10-5 ± 5.36 x 10-6 
CRAC-1F binding to POPC 1.05 x 10-5 ± 2.46 x 10-6 
CRAC-7 binding to POPC 1.66 x 10-5 ± 2.54 x 10-5 
CRAC+7 binding to POPC 5.32x 10-5 ± 5.41 x 10-6 
 
Table 5.3 Affinity of Peptides for 60% POPC and 40% Chol Liposomes Measured by 
LSPR 
Reaction KD (M) 
CRACWT binding to Chol 9.12 x 10-8 ± 4.87 x 10-10 
CRAC-1D binding to Chol 6.84 x 10-7 ± 7.30 x 10-9 
CRAC-1F binding to Chol 3.37 x 10-7 ± 9.73 x 10-8 
CRAC-7 binding to Chol 1.21 x 10-4 ± 5.43 x 10-4 
CRAC+7 binding to Chol 1.47 x 10-6 ± 1.48 x 10-5 
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5.2.6 Efficacy of peptide mutants to inhibit LtxA cytotoxicity correlates with their 
affinity for membrane Chol 
To determine if peptide-mediated inhibition of LtxA internalization by CRAC-1D
 
and CRAC-1F resulted in reduced LtxA cytotoxicity, we performed a cell cytotoxicity assay 
that measured cell viability in each of these cases.  As shown in Figure 5.10, our results 
indicate that CRAC-1D
 
and CRAC-1F inhibit LtxA cytotoxicity, but CRAC-7
 
and CRAC+7 
do not.  Inhibition of LtxA toxicity by CRAC-1D
 
and CRAC-1F are slightly less effective 
than inhibition by CRACWT, although this is not a statistically significant difference (data 
not shown).  Cell viability measurements correlate with the ability of these peptides to 
inhibit LtxA binding and internalization as shown in Figure 5.8 and Figure 5.9. 
 
 
Figure 5.2 Zeta Potential Measurements of Lipid Bilayers with and without Chol. 
Zeta potential was measured for liposomes composed of 100% POPC or 60% 
POPC/40% Chol.  As liposome Chol content increases, the zeta potential decreases 
suggesting the ions bound to the membrane also decrease.  A two-sample t-test was used 
to determine the level of significance between each experiment. ***P ≤ 0.001. 
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Figure 5.3 Octanol-Water Coefficients (log Kow) of the peptides. 
Octanol-water partition coefficients for each peptide were determined using the shake-flask 
method.  CRAC-7
 
and CRAC+7 have the highest overall net charge and greatest partitioning 
into the hydrophilic environment, as indicated by the lowest log Kow coefficient.  CRAC
-
1D and CRAC-1F have the lowest overall net charge and displayed the greatest partitioning 
into the hydrophobic environment, as indicated by the highest log Kow coefficients.  
CRACWT displayed a log Kow between CRAC
-7/CRAC+7 and CRAC-1D/CRAC-1F.  A one-
way analysis of variance followed by a Tukey test was used to determine the level of 
significance between each experiment. **P ≤ 0.01; N.S., not significant. 
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Figure 5.4 MRE CD Spectroscopy Data of Peptide Mutants in Solution. 
Spectral scans were performed in 10 mM phosphate buffer, using a peptide concentration 
of 0.25 mg/mL.  To ensure that the spectra represent the structure of only bound peptide, 
unbound peptide was removed using centrifugal filters.  MRE was calculated for each 
spectrum.  Filled in squares depict spectrum of CRACWT in solution.  Filled in circles depict 
spectrum of CRAC-1D in solution.  Filled in triangles depict spectrum of CRAC-1F in 
solution.  Open squares depict spectrum of CRAC-7 in solution.  Open circles depict 
spectrum of CRAC+7 in solution. 
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Figure 5.5 MRE CD Spectroscopy Data for Peptides Binding to 100% POPC Liposomes. 
Spectral scans were performed in 10 mM phosphate buffer, using a peptide concentration 
of 0.25 mg/mL.  To ensure that the spectra represent the structure of only bound peptide, 
unbound peptide was removed using centrifugal filters.  MRE was calculated for each 
spectrum.  Filled in squares depict spectrum of CRACWT in 100% POPC.  Filled in circles 
depict spectrum of CRAC-1D in 100% POPC.  Filled in triangles depict spectrum of CRAC-
1F in 100% POPC.  Open squares depict spectrum of CRAC-7 in 100% POPC.  Open circles 
depict spectrum of CRAC+7 in 100% POPC.  
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Figure 5.6 MRE CD Spectroscopy Data for Peptides Binding to 60% POPC/40% Chol 
Liposomes. 
Spectral scans were performed in 10 mM phosphate buffer, using a peptide concentration 
of 0.25 mg/mL.  To ensure that the spectra represent the structure of only bound peptide, 
unbound peptide was removed using centrifugal filters.  MRE was calculated for each 
spectrum.  Filled in squares depict spectrum of CRACWT in 60% POPC/40% Chol.  Filled 
in circles depict spectrum of CRAC-1D in 100% POPC.  Filled in triangles depict spectrum 
of CRAC-1F in 60% POPC/40% Chol.  Open squares depict spectrum of CRAC-7 in 60% 
POPC/40% Chol.  Open circles depict spectrum of CRAC+7 in 60% POPC/40% Chol. 
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Figure 5.7 MRE CD Spectroscopy Data for Each Peptide in Each Environment. 
Spectral scans were performed in 10 mM phosphate buffer, using a peptide concentration 
of 0.25 mg/mL.  To ensure that the spectra represent the structure of only bound peptide, 
unbound peptide was removed using centrifugal filters.  MRE was calculated for each 
spectrum.  Filled in squares depict spectrum of each peptide in solution.  Filled in circles 
depict spectrum of each peptide in solution in 100% POPC.  Filled in triangles depict 
spectrum of each peptide in 60% POPC/40% Chol.  
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Figure 5.8 Peptide-mediated inhibition of LtxA binding to Chol in GUVs. 
GUVs were composed of 66% POPC/33% Chol/1% NBD-PE (green).  In the absence of 
peptide, AF555-LtxA (red) bound to the membranes.  In the presence of CRAC-1D and 
CRAC-1F, at a peptide:toxin ratio of 100:1, LtxA was inhibited from binding to the 
membrane.  In the presence of CRAC-7 and CRAC+7, at a peptide:toxin ratio of 100:1, LtxA 
was able to bind to the GUV membrane.  The scale bar in the bottom right corner of each 
micrograph represents 10 µm. 
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Figure 5.9 Peptide-mediated inhibition of LtxA internalization in THP-1 cells. 
In the absence of peptide, AF555-LtxA (red) is located within THP-1 cells.  When the cells 
were preincubated with CRAC-1D and CRAC-1F for 30 min at a peptide:toxin ratio of 100:1, 
AF555-LtxA was unable to be internalized by the cells.  Preincubation of the cells with 
CRAC-7 and CRAC+7 for 30 min at a peptide:toxin ratio of 100:1 did not inhibit AF555-
LtxA internalization.  The scale bar in the bottom right corner of each micrograph 
represents 10 µm. 
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Figure 5.10 Effect of Mutant Peptides Inhibiting LtxA Cytotoxicity. 
LtxA and either CRACWT, CRAC-1D, CRAC-1F, CRAC-7, or CRAC+7were incubated with 
THP-1 cells for 3 hr, and the viability of the cells was measured using a trypan blue assay.  
The CRACWT, CRAC-1D, and CRAC-1F peptide, which bind to Chol, significantly inhibited 
the toxicity of LtxA.  The CRAC-7and CRAC+7 peptide, which do not bind to Chol, did not 
inhibit LtxA toxicity.  A one-way analysis of variance followed by a Tukey test was used 
to determine the level of significance between each experiment.  ***P ≤ 0.001; *P ≤ 0.05; 
N.S., not significant.  
 
5.3 Discussion 
A key issue with designing peptides that include CRAC domains is that the CRAC 
domain over predicts Chol binding, and a peptide which is designed to contain it may not 
display an affinity for Chol [102, 148, 151].  We undertook this work to improve upon the 
binding of CRACWT to the membrane and refine the current CRAC definition. 
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The interaction of peptides with lipid bilayers involves both electrostatic and 
hydrophobic forces [281].  We hypothesized that by decreasing the net charge of CRACWT 
we would increase peptide partitioning by increasing its propensity to bury into the 
hydrophobic membrane.  To accomplish this, we engineered four peptides, derived from 
our CRACWT peptide, with a varying degree of net charge. 
The four engineered variants of the CRACWT peptide were CRAC-1D, CRAC-1F, 
CRAC-7, and CRAC+7.  The net charges were altered by substituting Lys and/or Arg for a 
Glu, or a Glu for a Lys as shown in Table 5.1.  To determine the effect of these substitutions, 
we measured their affinities for Chol as well as their ability inhibit LtxA-mediated 
cytotoxicity in leukocytes.  We found that changes to the net charge of CRACWT affected 
the peptide’s affinity for Chol and its ability to inhibit LtxA activity.  
To understand how each mutant’s lipophilicity compared to that of our wild-type 
peptide, we performed a series of octanol-water partition measurements [282, 283].  The 
octanol-water coefficient (log Kow) measurements for CRAC
-1D and CRAC-1F, both with 
values greater than CRACWT, suggested they would have an increased partitioning into the 
hydrophobic membrane over the wild-type peptide thus leading to a greater affinity for 
Chol-containing model membranes.  Affinity measurements though, contradict this 
hypothesis, as the affinities of CRAC-1D and CRAC-1F for Chol were both one order of 
magnitude weaker than that of CRACWT.  It has been found that amphiphilic peptides with 
reduced helical structures in solution have a lower propensity to bind to minimally charged 
zwitterionic membranes such as the ones used in this study [281].  This finding is supported 
by our CD spectroscopy and LSPR results.  Peptides CRAC-1D, CRAC-1F, CRAC-7, and 
CRAC+7 have reduced secondary structures in solution compared to CRACWT in solution 
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and additionally these peptides have reduced affinities (Table 5.3) for the minimally 
charged 60% POPC/40% Chol liposomes (Figure 5.2). 
On the other end of the spectrum, CRAC-7 and CRAC+7 displayed a lower octanol-
water coefficient than CRACWT, which would suggest that they prefer to be in the 
hydrophilic environment more so than the wild-type peptide.  Our affinity measurements 
(Table 5.3) show this is the case for CRAC-7, but CRAC+7 displayed an affinity two orders 
of magnitude greater than CRAC-7.  A follow up zeta-potential measurement demonstrates 
that Chol decreases the surface charge of the membrane, leading to a more favorable 
binding environment for the positively charged CRAC+7.  Although there is an increase in 
binding, CRAC+7 fails to inhibit LtxA cytotoxicity, suggesting that when CRAC+7 interacts 
with the membrane, it does not specifically interact with Chol over POPC molecules. 
The low correlation between log Kow values and affinity suggest that the amino acid 
residues have a larger impact on the ability of the peptide to bind to Chol-containing 
membranes than we previously thought.  Studies have found the arrangement of amino 
acids and certain substitutions can lead to significant effects on the biological properties of 
peptides; our findings suggest that this could be the reason an increase in membrane affinity 
was absent in the mutant peptides with a reduced net charge [172, 284].  
Our findings also suggest that substitutions to the (X1-5) residues within the CRAC 
domain and residues that flank the CRAC domain (demonstrated with CRAC-1D and 
CRAC-1F) influence the peptide’s ability to bind to Chol-containing membranes.  The 
influence of these substitutions is unsurprising as Lys, Arg, and Glu can facilitate 
significant interactions with membrane lipids.  Studies have shown that Arg and Lys can 
form hydrogen bonds to the carbonyl and phosphate groups of lipids because of their 
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positive charge [184, 186].  Furthermore, a distinctive trait of charged amino acids is that 
they can snorkel (become incorporated within a lipid membrane and have their charged 
side chains remain at the water-membrane interface) and use their hydrogen bonding 
groups to attract water molecules and/or lipid headgroups [185, 285].  Arg has been shown 
to snorkel less efficiently than Lys due to its extra NH3 group, allowing it to attract more 
water into the membrane, increasing its ability to bind interfacially and perturb the 
membrane [184, 286].  On the opposite end of the spectrum, the acidic residues Glu and 
aspartate (Asp) require hydrogen bond donors, leading to more favorable interactions with 
the choline groups of phospholipids and water molecules at the water-membrane interface 
[184, 186].  These findings correlate with the snapshot obtained of CRACWT interacting 
with a PC/Chol membrane in silico (Figure 5.11).  The CRAC domain residues Glu, Lys, 
and Arg that surround the central Tyr are observed to reside at the membrane-water 
interface or just below the interface within the bilayer membrane. 
Accounting for the behavior of Arg and Lys, a substitution to one of these residues 
could disrupt a reaction that facilitates Chol binding.  For an Arg to Glu substitution as 
seen in CRAC-1F and a Lys to Glu substitution as seen in CRAC-1D, these changes could 
disrupt crucial hydrogen bonds between Arg and Lys and the carbonyl and phosphate 
groups of membrane lipids, thus decreasing the affinity of our peptides for the membrane 
and Chol [184, 186].  It is worth noting that these changes only highlight interactions with 
PC lipids and such changes do not induce differences in theses peptides’ affinity for 100% 
POPC liposomes.  With that in mind, the changes in affinities of these mutants for Chol-
containing membranes cannot be compared to the lack of change observed with these same 
mutants and 100% POPC.  The introduction of Chol within 60% POPC/40% Chol 
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liposomes alters the physical and chemical properties of the membrane which could allow 
such changes to have an effect on the peptide’s ability to bind to the membrane and its 
affinity for Chol-containing membranes [211, 287, 288]. 
The hydroxyl group of Chol is another key component in the interaction of a CRAC 
domain with the membrane [19, 140].  In the case of both CRAC-1D and CRAC-1F the basic 
Lys or Arg residues were substituted with acidic Glu residues.  The ability of the CRAC 
mutants, CRAC-1D and CRAC-1F, to form hydrogen bonds with lipid phosphate groups that 
reside near the hydroxyl groups of Chol diminished by 33% when compared to CRACWT 
[289].  Furthermore, the introduction of Glu residues, which hydrogen bond with choline 
and water, near the surface of the membrane, make it energetically less favorable for these 
polar residues to adopt a position near the Chol headgroups that are positioned further into 
the bilayer [184, 186, 290] further supporting the decreased affinity that was observed for 
CRAC-1D and CRAC-1F. 
In summary, our studies show that factors other than overall net charge of the 
peptide are important for the binding of CRACWT to Chol.  For the first time, these studies 
differentiate the possible role that the charged acidic and basic residues can have in altering 
the biological activity of our wild-type peptide, demonstrating that the interaction of 
CRACWT with Chol depends not only on the key Leu/Val, Tyr, and Lys/Arg residues but 
potentially on the residues surrounding these amino acids. 
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Figure 5.11 Zoomed in snapshot of CRACWT near a PC/Chol membrane. 
The Glu, Lys, and Arg residues can be seen at the water-membrane interface where they 
could potentially be interacting with PC lipid headgroups and/or Chol molecules.  The 
membrane is composed of PC carbons (cyan) and Chol molecules (magenta) [182].  The 
Phenylalanine residue is show in blue and the central and terminal Tyr residues are shown 
in green and red respectively. 
  
Glu 
Glu 
Arg 
Lys 
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Chapter 6  
Implementing Alanine Substitutions to 
Examine Key Residues in the Binding of a 
CRAC Domain to Cholesterol 
 
6.1 Introduction 
The biggest issue pertaining to the CRAC domain is still unaddressed, which is that 
the algorithm is not well defined and is very inaccurate.  This leads to the algorithm 
overpredicting Chol-binding domains and many of these domains found that contain a 
CRAC motif end up not having an affinity for Chol [102, 148, 150, 151].   
Previously, other groups have tried to investigate certain characteristics that 
regulate the CRAC domain’s affinity for Chol.  Studies were performed in which multiple 
mutations were investigated, including Tyr substitution with another aromatic amino acid 
(phenylalanine or tryptophan), alterations to the Leu/Val residue, which is thought to bury 
itself into the membrane and play a role in the CRAC domain’s ability to conform to the 
structure of Chol, and lastly alterations to the Lys/Arg residue, which is believed to allow 
the peptide to gravitate toward the water-membrane interface by way of their polar side 
chain [140, 143, 180, 181].  These studies did not reveal anything that is not already known 
and concluded that Tyr is necessary for Chol binding and that substitutions to either the 
first or last residue in the CRAC motif results in a decrease in affinity for Chol. 
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Literature has also suggested that the residues labeled as X must be nonpolar 
because those amino acids are assumed to span the nonpolar region of the membrane [140].  
CRACWT, which we have previously shown to have a strong affinity for Chol, contains two 
polar Glu residues in the X1 and X2 position.  In conjunction with studies that indicate Glu 
forms favorable interactions with the choline groups of PC lipids that facilitate binding to 
the membrane, this contradicts the notion that the X residues should be nonpolar [186]. 
The goal of this project was to demonstrate the role of each residue in the affinity 
for Chol, beyond the established requirements of Leu/Val, Tyr, and Arg/Lys and to gain a 
better understanding of the requirements needed for a CRAC domain to bind to Chol.  To 
accomplish this, a panel of ten peptides was synthesized based on the CRACWT peptide, 
where each peptide had one residue within the CRAC domain substituted with an alanine 
(Ala) residue, as listed in Table 6.1 [291, 292].  We hypothesized that this study would 
confirm Leu or Val, Tyr, and either the Arg or Lys as the key residues in the interaction 
with Chol.  Furthermore, measuring the affinity of each peptide for Chol will give us insight 
on each residue’s significance in the CRAC domain’s affinity for Chol and assist us and 
others in the future design of Chol-binding peptides. 
6.2 Results 
6.2.1 Mutations to the polar residues and to the central Tyr of CRACWT significantly 
increases log Kow  
To determine the tendency of each peptide to partition in a hydrophobic 
environment versus a hydrophilic environment we performed an octanol-water experiment 
to measure each peptide’s octanol-water coefficient (log Kow).  In this experiment, 1-
octanol serves as our model hydrophobic membrane and water serves as our model aqueous 
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environment.  Mutations to either Lys or Arg residues within CRACWT had the most 
pronounced effect on the log Kow as shown in Figure 6.1.  Each of these changes reduced 
the net charge of the peptide from +3 to +2 and increased the peptides hydrophobicity, 
resulting in an increased log Kow.  In addition, mutation of the central Tyr (Y10A) also 
increased log Kow, as Ala is more hydrophobic than Tyr, and led the peptide to favor a more 
hydrophobic environment as seen from the 10-fold increase in log Kow (Figure 6.1) [293, 
294]. 
 
Table 6.1 Peptide Sequences of Alanine mutants 
Residues underlined refer to the CRAC domain.  Residues highlighted in red and bolded 
are the residues we mutated from CRACWT peptide.  Each peptide was acetylated at the 
N-terminus and amidated at the C-terminus. 
Peptide Sequence 
CRACWT FDRARMLEEYSKRFKKFGY 
CRAC
L7A
 FDRARMAEEYSKRFKKFGY 
CRAC
E8A
 FDRARMLAEYSKRFKKFGY 
CRAC
E9A
 FDRARMLEAYSKRFKKFGY 
CRAC
Y10A
 FDRARMLEEASKRFKKFGY 
CRAC
S11A
 FDRARMLEEYAKRFKKFGY 
CRAC
K12A
 FDRARMLEEYSARFKKFGY 
CRAC
R13A
 FDRARMLEEYSKAFKKFGY 
CRAC
F14A
 FDRARMLEEYSKRAKKFGY 
CRAC
K15A
 FDRARMLEEYSKRFAKFGY 
CRAC
K16A
 FDRARMLEEYSKRFKAFGY 
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6.2.2 Amino acid mutations L7A, Y10A, and R13A of CRACWT have the largest effect on 
its affinity for Chol-containing membranes 
The three key residues in a CRAC definition are the initial Leu/Val, the central Tyr, 
and the final Lys/Arg.  To determine the effect of the initial, central, and final residues on 
the peptide’s affinity for Chol, we synthesized mutants with a substituted Ala at each of 
these positions and measured each mutant peptide’s affinity for Chol using LSPR 
measurements.  Affinity results for Chol-containing liposomes shown in Table 6.2 
corroborate with the CRAC definition that Leu, Tyr, and Arg are the key residues that 
facilitate the binding to Chol.  The affinities of these mutants for Chol were, on average, 
four orders of magnitude weaker than that of the wild-type peptide. 
6.2.3 Flanking residues facilitate binding to Chol 
Initially we did not know where the CRAC domain ended in CRACWT, as the 
CRAC definition proposed four possibilities: K12, R13, K15, and K16.  Utilizing LSPR 
we measured the change in affinity for Chol of four peptides, in which each peptide had a 
single mutation to either K12, R13, K15, or K16 and compared them to CRACWT.  We 
determined that R13 is the final residue of the CRAC domain as seen by the largest decrease 
in affinity between the four mutants and the third largest decrease overall (5.10 x 10-9 M to 
2.07 x 10-5 M), as seen in Table 6.2.  Furthermore, we found through changes to our wild-
type peptide that residues flanking the CRAC domain influence our wild-type peptide’s 
affinity for Chol.  These mutations (F14A, K15A, and K16A) decreased binding to Chol, 
on average, by two orders of magnitude.  The reduction in their affinity for Chol, as shown 
in Table 5.3, is much smaller than what we observed for the key CRAC residues (L7A, 
Y10A, and R13A).  These results suggest that residues between the key amino acids and 
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the residues flanking key amino acids could play a facilitative role in the binding of 
CRACWT to Chol-containing membranes. 
 
 
Figure 6.1 Octanol-Water Coefficients (log Kow) of Alanine Scanning Mutants. 
Octanol-water partition coefficients for each peptide were determined using the shake-flask 
method.  Mutations to Y10, R13, K15, and K16 produced the largest log Kow coefficients 
suggesting that these residues play a significant role in the wild-type peptide’s tendency to 
partition in a hydrophilic environment.  A one-way analysis of variance followed by a 
Tukey test was used to determine the level of significance between each mutant and 
CRACWT.  **** (P ≤ 0.0001). *P ≤ 0.05; N.S., not significant. 
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Table 6.2 Affinity Values of Mutant Peptides Binding to 60% POPC/40% Chol 
Liposomes by LSPR 
Reaction KD SPR (M) 
CRACWT binding to Chol 5.10 x 10-9 ± 4.37 x 10-9 
CRACL7A binding to Chol 4.27 x 10-5 ± 2.02 x 10-5 
CRACE8A binding to Chol 1.96 x 10-8 ± 1.37 x 10-9 
CRACE9A binding to Chol 2.76 x 10-8 ± 2.70 x 10-9 
CRACY10A
 
binding to Chol 3.64 x 10-5 ± 2.68 x 10-5 
CRACS11A
 
binding to Chol 1.64 x 10-8 ± 5.59 x 10-9 
CRACK12A
 
binding to Chol 1.53 x 10-7 ± 1.51 x 10-8 
CRACR13A
 
binding to Chol 2.07 x 10-5 ± 4.21 x 10-6 
CRACF14Abinding to Chol 3.48 x 10-7 ± 6.42 x 10-8 
CRACK15A
 
binding to Chol 2.77 x 10-7 ± 1.20 x 10-7 
CRACK16A
 
binding to Chol 3.19 x 10-6 ± 3.63 x 10-7 
 
6.3 Discussion 
The largest issue surrounding the CRAC domain is that it over predicts Chol 
binding, thus requiring experiments to determine if a motif has an affinity for Chol [102, 
148, 151].  We undertook this work to investigate the key residues that drive our wild-type 
peptide’s affinity for Chol with a secondary aim of trying to refine the CRAC motif’s 
definition to assist us and other groups in the future design of Chol-binding peptides. 
To accomplish our goal, we performed an alanine scanning procedure where each 
residue within the CRAC domain of our wild-type peptide was substituted with an alanine 
residue.  This method is widely employed to determine key residues involved in specific 
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interactions [292, 295-297].  Replacing a residue with alanine removes the side chain atoms 
after the β-carbon, which includes the functional group of the amino acid. This allows us 
to study the effects that a specific residue has on our interaction of interest.   
Among the mutants studied, we found that L7A, Y10A, and R13A had the largest 
effect on the wild-type peptide’s affinity for Chol.  Our results (Table 6.2) indicate that 
these residues are the three key amino acids defined in the CRAC definition, (L/V)-(X1-5)-
Y-(X1-5)-(K/R), and confirm our initial hypothesis while supporting the long standing 
CRAC motif definition [131].  Other groups have also demonstrated similar results; studies 
into single point mutations on CRAC segments found that mutations on either of the key 
residues resulted in a decreased or abolished ability to interact with Chol [142, 143, 145]. 
The initial Leu or Val uses its branched side chains to associate with the β face of 
Chol through van der Waals interactions [140, 180].  The final Lys or Arg can bury itself 
into the membrane bilayer and have its charged group sitting at the membrane surface, 
allowing it to attract and hydrogen bond water molecules and/or lipid headgroups [140, 
183-186].  Finally, the central Tyr is the most critical amino acid between the binding of 
the CRAC domain to Chol.  Tyr uses its hydroxyl group to electrostatically interacts with 
the sterol’s hydroxyl group while facilitating a CH-π stacking interaction with the B ring 
of Chol as well [140, 142, 182].  
Sites on a target protein that have a high tendency to bind to proteins, membranes, 
or other biomolecules, are referred to as “hot spots” [17, 19, 102, 298].  Systematic analyses 
of hot spots have found that these regions overlap with structurally conserved residues, as 
shown in the CRAC337 motif of LtxA [102, 298-302].  Furthermore, two of the most 
conserved residues found in “hot spots” are Arg, and Tyr which are also key residues within 
102 
 
the CRAC definition [131, 302, 303].  Although there have been no reports of protein hot 
spots containing CRAC domains or that a CRAC domain could be classified as one, the 
two share many similarities.  Taking this into account hot spot analyses could shed further 
light into why Tyr and Arg as well as the other key amino acids are significant in the CRAC 
motif’s interactions with Chol. 
Studies pertaining to CRAC domains have shown Tyr hydrogen bonds using its 
hydroxyl group, but hot spot analyses have shown that the hydrophobic surface, aromatic 
π interactions, and minimal rotatable bonds of Tyr are what allow it to contribute to the 
binding energy of its interaction without taking a large entropic penalty [304, 305].  
Furthermore, hot spot analyses suggests Arg can form up to five hydrogen bonds and due 
to the guanidinium π-system it can give the residue quasi-aromatic characteristics 
facilitating a stacking interaction with the membrane [304, 306-308].   
In summary, our studies show that the key residues of the CRAC definition, 
Leu/Val, Tyr, and Lys/Arg, are important for the binding of the wild-type peptide to Chol. 
Furthermore, our results suggest that residues between key amino acids are not as critical 
in the binding of our CRAC wild-type peptide to Chol-containing membranes, but they 
could play a supporting role.  The results of this study have given us a clearer picture on 
the amino acid requirements for the CRAC domain as well as the significance of each 
residue within our wild-type peptide CRACWT which will allow us to improve our wild-
type peptide’s affinity for Chol.  Lastly, with recent advances in peptide synthesis and 
screening, peptides are in a favorable spot to become successful drug discovery candidates 
and our findings could facilitate the development of a Chol-binding therapeutic peptide 
[309].  
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Chapter 7  
Inhibiting the Bacterial Toxins 
Streptolysin O and Pneumolysin O 
Utilizing Cholesterol Binding Peptides 
 
7.1 Introduction 
Many pathogens including bacterial toxins, recognize Chol as an initial step in their 
activity against cells [237, 310-312].  One class of toxins, the Chol-dependent cytolysins, 
depend on the presence of Chol for toxicity [310].  Previously, we described the potential 
of a peptide engineered to contain a CRAC motif (CRACWT) as a therapeutic agent against 
a toxin that targets Chol [19].  We demonstrated that CRACWT has a strong affinity for 
Chol and can inhibit a Chol-binding bacterial protein toxin.  Demonstrating the 
effectiveness of this Chol-binding peptide to inhibit the interaction between a virulence 
factor and Chol introduced a novel strategy that may have potential applications against 
other pathogens that bind to Chol.  This enables us to attack any Chol-dependent illnesses, 
as there are currently no viable approaches to inhibit this interaction.  More importantly, 
CRACWT exhibits no long-term toxicity to white blood cells, further bolstering its potential 
as an alternative therapeutic (Figure 4.10) [19].  This strategy has enormous potential for 
the treatment of bacterial infections, including ones that pose an antibiotic-resistant threat.  
Furthermore, the use of these types of peptides has the potential to replace or supplement 
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the use of antibiotics, which could lead to a decrease in the increasingly rising number of 
antibiotic resistant bacteria. 
In this work we focused on investigating the potential use of our antivirulence 
strategy in inhibiting other Chol-binding bacterial toxins.  Our model toxins include SLO 
and PLO.  SLO and PLO are secreted by bacteria that fall under the CDC’s list of emerging 
bacterial threats and both toxins utilize Chol in their method of action [3, 310].  Both toxins 
are structurally homologous and are secreted by most bacterial strains in the genus 
Streptococcus [310, 313, 314].  They are toxic to leukocytes and erythrocytes, and SLO 
and PLO require Chol for binding and cytotoxicity [273, 315, 316]. 
To measure the efficacy of CRACWT in inhibiting these toxins, white blood cell 
cytotoxicity and red blood cell hemolytic assays were performed using THP-1 cells and 
sheep erythrocytes.  The affinity of the CRACWT peptide for Chol is several orders of 
magnitude stronger than reported affinity of PLO for Chol (4 × 10−7 M) suggesting that the 
peptide may inhibit binding of PLO to Chol-containing membranes [19, 273].  The affinity 
of SLO for Chol has yet to be determined but due to the mechanistic similarities of both 
toxins we hypothesize that CRACWT will inhibit SLO as well [4, 310, 314].  From our study 
we found that CRACWT is an effective agent in inhibiting the toxicity of SLO and PLO 
toward THP-1 cells, and the toxicity of PLO towards sheep erythrocytes, thus 
demonstrating the peptide’s potential as a novel alternative therapy for bacterial toxin-
mediated infections. 
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7.2 Results 
7.2.1 CRACWT inhibits SLO cytotoxicity in THP-1 cells 
To investigate the possibility of inhibiting SLO cytotoxicity using the Chol-binding 
peptide CRACWT we employed a cell cytotoxicity experiment with THP-1 cells.  We 
incubated THP-1 cells with SLO alone or in combination with the CRACWT peptide for 24 
hr.  As shown in Figure 7.2, CRACWT inhibited the activity of SLO almost completely at a 
peptide to toxin ratio of 40:1.  To determine the half maximal peptide inhibitory 
concentration (IC50) of the CRAC
WT peptide, the data were fitted to a sigmoidal curve in 
ORIGIN® PRO 2016. The results of this fit predict an IC50 of 7.4 µM for CRAC
WT peptide 
against SLO in THP-1 cells, that is, a peptide to toxin molar ratio of 1.3. 
7.2.2 CRACWT inhibits PLO cytotoxicity 
We next investigated the possibility of inhibiting PLO activity using the Chol-
binding peptide CRACWT.  To determine if CRACWT can inhibit PLO binding to Chol and 
subsequent toxicity, we incubated THP-1 cells with PLO alone or in combination with the 
CRACWT peptide for 2 hr.  As shown in Figure 7.4, CRACWT inhibited the activity of PLO 
almost completely at a peptide to toxin ratio of 1000:1.  The results of this fit predict an 
IC50 of 8.5 µM for CRAC
WT peptide, that is, a peptide to toxin molar ratio of 36.5. 
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Figure 7.1 SLO is toxic to THP-1 Cells over time. 
THP-1 cells were treated with 40.5 µg of SLO for 24 hr, and the viability of the cells was 
measured using a trypan blue assay. Squares represent the control group without SLO, 
circles represent cells incubated with SLO. 
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Figure 7.2 CRACWT peptide inhibits SLO-mediated toxicity. 
SLO and CRACWT were incubated with THP-1 cells for 24 h, and the viability of the cells 
was measured using a trypan blue assay. The CRACWT peptide, which binds to Chol, 
inhibited the toxicity of SLO. A one-way analysis of variance followed by a Tukey test 
was used to determine the level of significance between each experiment. **P ≤ 0.01; *P 
≤ 0.05; N.S., not significant. 
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7.2.3 CRACWT inhibits PLO hemolysis 
Lastly, we investigated the possibility of inhibiting PLO hemolysis of sheep 
erythrocytes using the Chol-binding peptide CRACWT.  To determine if CRACWT could 
prevent the hemolytic activity of PLO, we incubated sheep erythrocytes with PLO alone or 
in combination with the CRACWT peptide.  As shown in Figure 7.5, CRACWT inhibited the 
activity of PLO almost completely at a peptide to toxin ratio of 1:1.  The results of this fit 
predict an IC50 of 40.6 nM for CRAC
WT peptide, that is, a peptide to toxin molar ratio of 
0.4. 
 
 
Figure 7.3 PLO is toxic to THP-1 Cells over time. 
PLO was incubated with THP-1 cells for 2 h, and the viability of the cells was measured 
using a trypan blue assay. Squares represent the control group without PLO, circles 
represent cells incubated with 4 μg of PLO. 
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Figure 7.4 CRACWT peptide inhibits PLO toxicity. 
PLO and CRACWT were incubated with THP-1 cells for 2 h, and the viability of the cells 
was measured using a trypan blue assay. The CRACWT peptide, which binds to Chol, 
inhibited the toxicity of PLO. A one-way analysis of variance followed by a Tukey test 
was used to determine the level of significance between each experiment. **P ≤ 0.01; *P 
≤ 0.05; N.S., not significant. 
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Figure 7.5 CRACWT peptide inhibits PLO hemolysis. 
PLO and CRACWT were incubated with sheep erythrocytes for 1 h, and the viability of the 
cells was determined by measuring the absorbance of the supernatant. The CRACWT 
peptide, which binds to Chol, inhibited the toxicity of PLO. A one-way analysis of variance 
followed by a Tukey test was used to determine the level of significance between each 
experiment. ***P ≤ 0.001; **P ≤ 0.01; *P≤0.05; N.S., not significant. 
 
7.3 Discussion 
Traditional antibiotics are the usual route of treatment with patients presenting with 
Streptococcus infections [317].  In conjunction with the increasing number of other 
bacterial infections, the number of antibiotics prescribed annually has reached 250 million 
[318].  Due to the overuse of antibiotics to treat bacterial infections, there are greater 
opportunities for infectious bacteria to evolve and develop antibiotic resistance [3, 319].  
Furthermore, it is estimated that the cost arising from antibiotic-resistant infections will 
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reach US$100 trillion worldwide by 2050, and will have implications on the economic 
growth while threatening to reverse the advancements made on antibacterial treatments 
within the last century [320, 321].  The increasing number of antibacterial-resistant 
organisms has complicated the ability to treat resulting infections, and if little is done to 
combat the overuse of antibiotics and the increasing number of antibiotic-resistant bacteria 
the effective use of antibiotics will come to an end.  To alleviate such a crisis from 
occurring, we seek to find an alternative approach that will not increase the bacterial 
survival pressure which would reduce bacterial mutation rates [322].  By focusing on 
inhibiting the toxins that are secreted by the pathogenic bacteria, we could inhibit the 
virulence of the pathogenic bacteria without targeting the organisms directly.  
Streptococci bacteria employ many virulence factors that are critical to their ability 
to fight off the host’s immune system, bind to their target cell, and facilitate the process of 
lysing the cell [323-326].  Among them, PLO and SLO are key to a successful infection by 
the Streptococcus genus [327-331].  Both toxins can form pores in membranes containing 
Chol thus leading to inflammation and the death of the host’s immune cells in the process 
[310, 332, 333].  Furthermore, it has been shown that by preventing such binding to the 
cell membrane, through mutations to the bacterium that prevent toxin secretion or to the 
primary structure of the toxin, the virulence of these bacteria was reduced in animal studies 
[332, 333].  This suggests that the development of novel therapeutics that target the toxin 
secreted can be a viable approach to treating these infections, which in turn would decrease 
the use of antibiotics and decrease the rate of evolution by antibiotic-resistant bacteria. 
The main goal of this study was to explore a possible alternative treatment for 
bacterial infections.  Previously we have demonstrated the ability of a Chol-binding 
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peptide, CRACWT, to inhibit the bacterial toxin LtxA of A. actinomycetemcomitans, which 
utilizes Chol in its mode of toxicity [17, 19].  Due to the requirement of Chol for the binding 
of SLO and PLO to cell membranes we investigated the ability of our peptide, CRACWT, 
to inhibit the cytotoxicity and hemolytic activity of these two toxins [19, 310].  We 
employed sheep erythrocytes and THP-1 cells to measure the inhibitory action of CRACWT 
against the hemolytic and cytotoxic activities, respectively, of SLO and PLO.  
Here, we provide evidence that CRACWT has activity against SLO and PLO in a 
concentration-dependent manner.  CRACWT was successful in inhibiting both SLO and 
PLO toxins from killing THP-1 cells.  The IC50 of CRAC
WT for SLO was comparable to 
that of PLO, and because the affinity of SLO for Chol has not been reported, this could 
suggest that the affinity of SLO for Chol is similar to that of PLO.  Furthermore, for our 
hemolysis assays with sheep erythrocytes, the IC50 of CRAC
WT against PLO was much 
lower than what we found for THP-1 cells.  This could be a result of lower total Chol 
concentration in the membranes of sheep erythrocytes versus THP-1 cells, thus requiring a 
lower amount of peptide for inhibition [334, 335].  Regarding the hemolytic activity of 
SLO, no activity was detected.  A possible explanation for this occurrence is the 
inactivation of SLO, which is an oxygen-labile protein that is reduced in solution and 
inactivated in storage conditions between 2-8 °C [327, 336, 337]. 
Other groups have also investigated alternative antibacterial treatments.  Three such 
compounds used as alternative therapeutics against SLO and PLO are allicin, a component 
of garlic, β-sitosterol which is a plant sterol, and cyclodextrins [316, 338-342].  In vitro 
studies of allicin have shown that it inhibits SLO and PLO toxicity by binding to the 
cysteine residue within a conserved amino acid sequence.  This sequence is thought to play 
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a role in toxin binding to the membrane or affect the toxin’s conformation needed for 
activity [343, 344].  Studies of β-sitosterol have shown it acts by binding directly to the 
toxin, more specifically the threonine and Leu residues required for Chol binding, thus 
inhibiting the toxin form binding to Chol within the cell membrane [135].  In the case 
of cyclodextrins, which have a strong affinity for Chol, they act by extracting Chol from 
the membrane and reducing the number of possible binding sites for such toxins [237, 345].  
Although these compounds have presented a viable alternative in the treatment against 
the bacterial toxins SLO and PLO, they do come with limitations.  Allicin’s drawback 
lies in its instability in physiological fluids, which significantly impacts its ability to be 
used as a therapeutic [346].  β-sitosterol is unstable while bound to the toxin, and a 
correlation between increased plasma concentrations of β-sitosterol and an increase in 
the rate of heart disease in men has been found [338].  Lastly, the downside of 
cyclodextrins is that by removing membrane Chol they alter the cell’s processes and reduce 
the cell’s viability [235, 347]. 
In summary, we have demonstrated that CRACWT possesses the capacity to inhibit 
SLO, PLO, and possibly other Chol-dependent cytolysins due to how structurally similar 
they are [314].  Previously, we have demonstrated that the CRACWT peptide does not 
induce cytotoxicity in host cells, making it a viable therapeutic candidate [235].  The ability 
of CRACWT to inhibit toxin activity by blocking the toxin’s interaction with Chol in the 
cell membrane is a novel therapeutic concept that could have an impact in not only reducing 
the rise of antibiotic-resistant bacteria but could also be used in the treatment of other 
pathogens that utilize membrane Chol.   
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Chapter 8  
Concluding Remarks 
8.1 Project Outcomes 
We found that LtxA requires Chol to be present in the membrane to induce toxicity, 
and this dependence on Chol enabled us to explore this interaction as a means of inhibiting 
the activity of the toxin.  Initially, as a method of inhibition, we utilized Chol-containing 
liposomes as an alternative binding site of LtxA.  This prevented the toxin from binding to 
the cell and opened the door to other novel therapeutic approaches including the use of a 
Chol-binding peptide (CRACWT) derived from LtxA’s CRAC domain to inhibit LtxA 
cytotoxicity. 
CRACWT acts by binding to Chol-containing membranes with a strong affinity, as 
does our model toxin LtxA.  Once incubated with THP-1 cells, CRACWT binds to Chol 
within the cell’s membrane and prevents subsequent LtxA from binding to the membrane 
and becoming internalized, this in turn renders the toxin ineffective.  During this binding 
interaction with Chol, CRACWT sits near the water-membrane interface suggesting that the 
inhibition of LtxA due to CRACWT occurs through obstruction of potential Chol binding 
sites.  This technique was the first time a peptide derived from a Chol-binding bacterial 
toxin was used therapeutically against the toxin that it was derived from. 
In the interaction between membrane Chol and CRACWT, the structure of the Chol 
molecule plays a significant role.  We demonstrated that the hydroxyl group of Chol is key 
in its successful binding with CRACWT and in addition, the tail structure of Chol facilitates 
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binding of the peptide as well.  This demonstrates key interactions between the CRAC 
domain and Chol occur at the hydroxyl and tail group of Chol. 
The CRAC peptide’s charge and sequence also influence its ability to bind to 
membrane Chol.  We found that decreasing or increasing the net charge of a CRAC peptide 
relative to CRACWT affected the peptide’s affinity for Chol-containing membranes.  A 
decrease in net charge resulted in the reduction of the peptide’s affinity for Chol-containing 
membranes while an increase in net charge significantly reduced the peptide’s affinity for 
Chol-containing membranes.  This suggests that electrostatic interactions can influence the 
CRAC domain’s interaction with Chol.  Furthermore, we found that the most critical 
residues involved in the interaction between CRACWT and Chol are the initial Leu, the 
central Tyr, and the final Arg.  These results fulfill the CRAC defection outlined in the 
introduction of this work.  In addition, our alanine mutant results described in Chapter 6 
demonstrate that residues residing between the central Tyr and the initial and final residues 
of the CRAC domain can contribute to the peptide’s affinity for Chol as well. 
Lastly, we found that CRACWT can be utilized to inhibit other Chol-binding 
bacterial toxins.  The affinity of CRACWT was strong enough to outcompete two 
Streptococcal toxins, SLO and PLO.  This demonstrated the broad-spectrum applicability 
of CRACWT as a potential therapeutic not only for Chol-binding bacterial toxins but for 
viruses which utilize Chol in their toxic mechanisms. 
8.2 Contributions to the Field 
Throughout this work contributions were made to four areas.  1) The interaction of 
LtxA to Chol-containing membranes and cells.  2) The interaction of a CRAC peptide to 
Chol-containing membranes and cells.  3) The significance of amino acid residues within 
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a CRAC domain pertaining to its ability to bind to Chol-containing membranes and cells.  
4) The broad-spectrum applicability of a CRAC peptide in inhibiting Chol-utilizing toxins. 
Utilizing an MβCD study we demonstrated that the binding of LtxA to THP-1 cells 
and model membranes is dependent on the presence of Chol.  For this interaction we 
contributed thermodynamic information pertaining to the binding between LtxA and 
synthetic PC and PC/Chol membranes. 
Through this work we introduced a novel therapeutic approach using a Chol-
binding peptide derived from the CRAC domain of a bacterial toxin. We demonstrated that 
the CRAC domain of LtxA can be used to bind to Chol and prevent LtxA from binding to 
the cell membrane and subsequently becoming internalized, thus successfully inhibiting 
the toxin.  We also demonstrated experimentally, for the first time, that the interaction 
between a CRAC peptide and Chol is dependent on the peptide’s interaction with the 
hydroxyl group of Chol and the tail end of Chol. 
The lack of affinity information for a CRAC peptide’s interaction with PC and 
PC/Chol liposomes allowed us to contribute thermodynamic and kinetic information 
pertaining to these interactions with the aid of ITC and LSPR experiments respectively.  In 
addition to previous experimental and in silico studies, we contributed secondary structure 
analysis pertaining to CRAC peptides in solution, while interacting with Chol-free 
membranes, and while interacting with Chol-containing membranes. 
Varying the primary structure of the CRAC peptide allowed us to investigate the 
effects of single-residue substitution as well as the effects of net charge on the peptides 
ability to bind to Chol-containing membranes.  We found that changes to the overall net 
charge of the peptide can affect its membrane-binding ability.  In addition, we found that 
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each residue can also play a facilitating role in the peptide’s ability to bind to Chol-
containing membranes. 
8.3 Conclusion 
LtxA secreted by A. actinomycetemcomitans is chiefly dependent on the presence 
of Chol within the membrane for binding.  Using Chol-binding peptides that inhibit LtxA’s 
ability to bind to the membrane presented a novel alternative therapeutic approach to 
combating this bacterial toxin.  The strong affinity of CRACWT for Chol-containing 
membranes enabled CRACWT to successfully prevent- LtxA-mediated cytotoxicity.  
Additionally, the inhibition of this interaction allowed us to explore the broad-spectrum 
applicability of CRACWT and demonstrate that it can inhibit the cytotoxicity and hemolysis 
of other bacterial toxins as well. 
Demonstrating the effectiveness of this Chol-binding peptide to inhibit the 
interaction between numerous virulence factor and Chol introduces a novel strategy.  We 
gain the ability to attack any Chol-dependent illnesses, as there are currently no viable 
approaches to inhibit this interaction.  More importantly, CRACWT exhibits no long-term 
toxicity to white blood cells, further bolstering its potential as an alternative therapeutic.  
This strategy has enormous potential for the treatment of not just illnesses caused by 
bacteria, but also those caused by viruses that utilize Chol, including HIV, the influenza 
virus, and the herpes simplex virus.  Furthermore, the use of these types of peptides has the 
potential to replace or supplement the use of antibiotics, leading to a decrease in the 
increasingly rising number of antibiotic resistant bacteria. 
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